[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4976
1. Diezhandino MP, González C, Rivera MI: [Case imaging: 2. Cerebral and pulmonary metastasis of gestational choriocarcinoma]. Radiologia; 2006 Mar-Apr;48(2):106, 112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case imaging: 2. Cerebral and pulmonary metastasis of gestational choriocarcinoma].
  • [Transliterated title] Casos en imagen: 2. Metástasis cerebrales y pulmonares de coriocarcinoma gestacional.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / secondary. Choriocarcinoma / diagnostic imaging. Choriocarcinoma / secondary. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / secondary. Tomography, X-Ray Computed. Uterine Neoplasms / pathology


2. Zhou W, Li J, Wang X, Hu R: Stable knockdown of TPPP3 by RNA interference in Lewis lung carcinoma cell inhibits tumor growth and metastasis. Mol Cell Biochem; 2010 Oct;343(1-2):231-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable knockdown of TPPP3 by RNA interference in Lewis lung carcinoma cell inhibits tumor growth and metastasis.
  • In the present study, we knocked down TPPP3 in Lewis lung carcinoma (LLC) cells with the same RNAi construct, and observed a retarded tumor cell growth in vitro.
  • Furthermore, C57BL/6 mice that received subcutaneously injected LLC cells in which TPPP3 was knocked down showed a pronounced reduction in tumor progression.
  • The migration/invasion activity of TPPP3-knockdown LLC cells was significantly suppressed in a transwell chamber migration assay.
  • When these cells were injected into the tail veins of C57BL/6 mice, they exhibited milder lung metastasis compared with control tumor cells.
  • Taken together, these findings suggested that the TPPP3 gene played an important role in tumorigenesis and metastasis, and it could potentially become a novel target for cancer therapy.
  • [MeSH-major] Carcinoma, Lewis Lung / pathology. Cell Adhesion Molecules / physiology. Cell Division. Gene Knockdown Techniques. Neoplasm Metastasis / prevention & control. RNA Interference
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. DNA Primers. Male. Mice. Mice, Inbred C57BL

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):559-64 [16098726.001]
  • [Cites] Traffic. 2004 Jul;5(7):470-7 [15180824.001]
  • [Cites] Mol Cells. 2009 Jan 31;27(1):1-3 [19214428.001]
  • [Cites] Curr Biol. 2004 Sep 21;14(18):R797-805 [15380094.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29531-9 [17693641.001]
  • [Cites] J Hum Genet. 2002;47(5):266-8 [12032596.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:83-117 [9442869.001]
  • [Cites] J Hum Genet. 1999;44(2):121-2 [10083737.001]
  • [Cites] Exp Cell Res. 2007 Dec 10;313(20):4091-106 [18028908.001]
  • [Cites] Biochemistry. 2006 Nov 21;45(46):13818-26 [17105200.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):425-39 [15349817.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):6249-59 [15564385.001]
  • [Cites] Cell Struct Funct. 1994 Apr;19(2):57-62 [7923398.001]
  • [Cites] Biochem Cell Biol. 1992 Oct-Nov;70(10-11):835-41 [1297349.001]
  • [Cites] Trends Cell Biol. 2005 Feb;15(2):76-83 [15695094.001]
  • [Cites] Acta Biomater. 2007 Jul;3(4):413-38 [17540628.001]
  • [Cites] Curr Opin Cell Biol. 1995 Feb;7(1):72-81 [7755992.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Jan;35(1):39-50 [12467646.001]
  • [Cites] Mol Cell Biochem. 2010 Jan;333(1-2):91-8 [19633818.001]
  • [Cites] Infect Genet Evol. 2009 Dec;9(6):1275-86 [19778640.001]
  • [Cites] Biochemistry. 2002 Jul 9;41(27):8657-64 [12093283.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):61-7 [10047528.001]
  • (PMID = 20571904.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ceacam9 protein, mouse; 0 / Cell Adhesion Molecules; 0 / DNA Primers
  •  go-up   go-down


3. Adachi H, Maehara T: [Surgical treatment and outcome of multiple primary lung cancers]. Kyobu Geka; 2010 May;63(5):347-51; discussion 351-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and outcome of multiple primary lung cancers].
  • We assessed the selection of the type of pulmonary resection, operative morbidity, mortality and the outcome of our 14 cases who underwent surgical treatment for multiple primary lung cancer.
  • The survival rate was higher than that of T4 (metastasis to the same lung lobe) cases and M1 (metastasis to another lung lobes) cases.
  • With this result, we consider that postoperative good survival can be expected by the aggressive surgical approach for cases of multiple primary lung cancer, despite it is difficult to distinguish multiple primary lung cancers and metastatic cancers preoperatively.
  • On the other hand, the opportunity to treat early-stage lung cancer is possibly increase with the spread of medical checkup using computed tomography (CT), it will be necessary to introduce limited surgery at 1st operation to keep post-operative pulmonary function, considering another surgery for the 2nd primary lung cancer.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446600.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Dagnault A, Ebacher A, Vigneault E, Boucher S: Retrospective study of 81 patients treated with brachytherapy for endobronchial primary tumor or metastasis. Brachytherapy; 2010 Jul-Sep;9(3):243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of 81 patients treated with brachytherapy for endobronchial primary tumor or metastasis.
  • PURPOSE: The purpose of this retrospective study is to evaluate the role of endobronchial brachytherapy in the palliation of lung cancer (or metastasis) symptoms and its potential impact on overall survival.
  • The projection of the tumor was drawn by the bronchoscopist to help the radiation oncology team to perform the dosimetry.
  • RESULTS: Seventy-three percent of the patients were treated for primary lung cancer.
  • The remaining patients were treated for lung metastasis of other primary.
  • [MeSH-major] Brachytherapy / methods. Bronchial Neoplasms / radiotherapy. Bronchial Neoplasms / secondary. Carcinoma / radiotherapy. Carcinoma / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20122873.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Nanashima A, Sumida Y, Yamasaki N, Takeshita H, Tagawa T, Tobinaga S, Araki M, Kunizaki M, Sawai T, Nagayasu T: Simultaneous hepatic and pulmonary resection for metastatic colonic carcinoma under thoraco-laparotomy with right oblique incision: case report. Hepatogastroenterology; 2009 Sep-Oct;56(94-95):1362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous hepatic and pulmonary resection for metastatic colonic carcinoma under thoraco-laparotomy with right oblique incision: case report.
  • To achieve complete resection of metastatic colonic carcinoma in the liver and lung, thoracolaparotomy-assisted simultaneous resection was attempted in a 60-year-old male patient who had previously undergone sigmoidectomy for primary sigmoid colon carcinoma.
  • A solitary liver metastasis was observed in segment 7 and a solitary lung metastasis was located in segment 6 of the right lower lung.
  • A partial hepatectomy was performed followed by a segmental resection of the lung.
  • The patient had no remarkable complications including pulmonary complication after surgery and was discharged at day 20 post-operation.
  • For metastatic tumors simultaneously located in the right subphrenic part of the liver and the lower part of the right lung, thoraco-laparoscopy-assisted complete resection is a safe and useful option to achieve curative treatment.
  • [MeSH-major] Colonic Neoplasms / surgery. Laparotomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Thoracotomy / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950792.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Assouad J, Masmoudi H, Berna P, Steltzlen C, Radu D, Riquet M, Grunenwald D: Isolated rib metastases from renal cell carcinoma. Interact Cardiovasc Thorac Surg; 2010 Feb;10(2):172-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated rib metastases from renal cell carcinoma.
  • Osseous metastases of renal cell carcinoma (RCC) are the second most frequent location after lung metastases.
  • The purpose of the current study is to focus on a particular subset, the isolated rib metastases (IRM).
  • All had previous radical nephrectomy for clear-cell renal cancer.
  • The mean disease-free interval (DFI) after renal cancer treatment was 25 months.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Ribs / pathology. Thoracic Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805505.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Baierlein SA, Wistop A, Looser C, Bussmann C, von Flüe M, Peterli R: Primary pancreatic neoplasia or metastasis from colon carcinoma? Acta Gastroenterol Belg; 2008 Oct-Dec;71(4):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic neoplasia or metastasis from colon carcinoma?
  • INTRODUCTION: The pancreas is an unusual but occasionally favored target for metastasis from other primary cancers.
  • Metastases have been described for various non-hematologic neoplasms, such as renal-cell carcinoma, pulmonary small-cell carcinoma, melanoma and gastric carcinoma.
  • CASE REPORT: We report the case of a 77-year old man with a mass in the pancreatic head five years after anterior resection for adenocarcinoma of the colon and three years after resection of a lung metastasis.
  • DISCUSSION: It is rare to have solitary metastases to the pancreas which clinically may mimic a primary neoplasm of the pancreas.
  • Clinical features, as well as MRI and PET findings in patients with pancreatic metastasis from colon carcinoma are similar to those of primary pancreatic ductal adenocarcinoma.
  • The diagnosis of metastasis should be considered when patients have a pancreatic mass and a history of non-pancreatic malignant lesions.
  • Radical resection may prolong survival in patients if the pancreas is the only locus for metastasis at the time of diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Neoplasms, Second Primary / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317283.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


8. Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B, Gao J, Chen Z: Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology; 2008;82(2):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.
  • In this study, we investigated the effect of artemisinin on tumor growth, lymphangiogenesis, metastasis and survival in mouse Lewis lung carcinoma (LLC) models.
  • We found that orally administered artemisinin inhibited lymph node and lung metastasis and prolonged survival without retarding tumor growth.
  • Consistent with the decrease in lymph node metastasis, tumor lymphangiogenesis and expression of vascular endothelial growth factor C (VEGF-C) was significantly decreased in artemisinin-treated mice, as compared to control mice.
  • These data indicate that artemisinin may be useful for the prevention of lymph node metastasis by downregulating VEGF-C and reducing tumor lymphangiogenesis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Artemisinins / pharmacology. Carcinoma, Lewis Lung / drug therapy. Vascular Endothelial Growth Factor C / drug effects
  • [MeSH-minor] Administration, Oral. Animals. Female. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Lymphangiogenesis / drug effects. Lymphatic Metastasis / prevention & control. Mice. Mice, Inbred C57BL. Neoplasm Metastasis / prevention & control. Survival Rate. p38 Mitogen-Activated Protein Kinases / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18667841.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 0 / Vascular Endothelial Growth Factor C; 9RMU91N5K2 / artemisinine; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


9. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ: CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A; 2007 Oct 2;104(40):15735-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.
  • Chemokines and chemokine receptors have been posited to have important roles in several common malignancies, including breast and lung cancer.
  • Using a combination of overexpression and RNA interference, we establish that CXCR7 promotes growth of tumors formed from breast and lung cancer cells and enhances experimental lung metastases in immunodeficient as well as immunocompetent mouse models of cancer.
  • Furthermore, immunohistochemistry of primary human tumor tissue demonstrates extensive CXCR7 expression in human breast and lung cancers, where it is highly expressed on a majority of tumor-associated blood vessels and malignant cells but not expressed on normal vasculature.
  • Taken together, these data suggest that CXCR7 has key functions in promoting tumor development and progression.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 2000 Jul 4;39(26):7651-61 [10869171.001]
  • [Cites] Cancer Res. 1990 May 15;50(10):2973-8 [2159367.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):186-9 [12673677.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1381-9 [14597737.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8093-101 [14603250.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2853-60 [14978086.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):171-8 [15081542.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21569-74 [10419462.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5084-95 [15958552.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):261-6 [15978329.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6493-7 [16061624.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8273-80 [16322285.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):30-41 [16046252.001]
  • [Cites] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):126-30 [15471215.001]
  • [Cites] Yeast. 2000 Dec;17(4):294-301 [11119306.001]
  • (PMID = 17898181.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA107469; United States / NIAID NIH HHS / AI / U19 AI056690; United States / NCI NIH HHS / CA / P50 CA93990; United States / NCI NIH HHS / CA / R24CA083099; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / R24 CA083099; United States / NIAID NIH HHS / AI / 1 U19 AI056690; United States / NCI NIH HHS / CA / P50 CA093990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCR7 protein, human; 0 / RNA, Neoplasm; 0 / Receptors, CXCR; 0 / Zebrafish Proteins
  • [Other-IDs] NLM/ PMC1994579
  •  go-up   go-down


10. Kume H, Nyoumura S, Niimi A, Fujimura T, Fukuhara H, Ishikawa A, Nishimatsu H, Tomita K, Takeuchi T, Kitamura T: [Bladder recurrence of renal cell carcinoma: report of two cases]. Nihon Hinyokika Gakkai Zasshi; 2007 Jul;98(5):718-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Through the examination of hypercalcemia, bone metastases and a bladder tumor were found.
  • Transurethral resection of the bladder tumor was performed and histological examination revealed that the tumor was clear cell carcinoma similar to the right renal tumor.
  • In spite of the adjuvant immunotherapy including interferon alpha, gamma and interleukin-2, 16 months later multiple lung metastases appeared.
  • Histologically the tumor was clear cell carcinoma similar to the left renal tumor.
  • In both cases the metastasis was confirmed histologically.
  • As in both cases the recurrent bladder cancers were confined in the mucosa, these metastases were thought to be caused by implantation.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / secondary. Male. Urinary Bladder / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682452.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Kassab R, Hamdan R, El AB, Azar R, Salame E: [Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]. Ann Cardiol Angeiol (Paris); 2006 Oct;55(5):286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases].
  • [Transliterated title] Effet bénéfique du sildénafil en postopératoire dans le rétrécissement mitral compliqué d'hypertension artérielle pulmonaire précapillaire: a propos de deux cas.
  • Pulmonary hypertension is a serious disorder, difficult to treat especially in the severe forms.
  • Sildenafil, a phosphodiesterase 5 specific inhibitor, has been largely evaluated in primary pulmonary hypertension, and in some cases of secondary pulmonary hypertension including parenchymal and thromboembolic diseases; it has not yet been evaluated in severe pulmonary hypertension with elevated pre-capillary resistance in operated mitral stenosis.
  • We report the cases of two patients operated from mitral valve replacement for severe mitral stenosis with elevated pre-capillary resistance, where oral sildenafil, introduced empirically immediately after the surgical procedure at the dose of 50 mg/d, permitted a significant decrease in pulmonary pressures and resistances, allowing a rapid withdrawal of nitric oxide and reducing therefore hospitalization time in the intensive care unit.
  • We think that this simple treatment, with or without association to nitric oxide, should be generalized to persistent pulmonary hypertension following cardiac surgery.
  • [MeSH-major] Hypertension, Pulmonary / complications. Hypertension, Pulmonary / drug therapy. Mitral Valve Stenosis / complications. Mitral Valve Stenosis / surgery. Phosphodiesterase Inhibitors / therapeutic use. Piperazines / therapeutic use. Sulfones / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • Hazardous Substances Data Bank. SILDENAFIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17078267.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 0 / Piperazines; 0 / Purines; 0 / Sulfones; BW9B0ZE037 / Sildenafil Citrate
  •  go-up   go-down


12. Atmani A, Topart P, Vandenbroucke F, Louzi A, Ferrand L, Lozac'h P: Metachronous cancer of gastroplasty after esophagectomy. Dis Esophagus; 2006;19(6):512-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous cancer of gastroplasty after esophagectomy.
  • We reviewed two cases of adenocarcinoma of the gastric tube used for reconstruction after esophagectomy for cancer.
  • The first case gastric cancer was detected during follow-up by endoscopic examination.
  • Total resection of the gastric tube and reconstruction by Roux-en-Y was performed each time.
  • In the second case the tumor was revealed via thoracic pain.
  • Chemotherapy, using carboplatin-5-fluorouracil, was performed because of lung metastasis but the patient died 1 year later.
  • The incidence of gastric tube cancer after esophagectomy has recently increased in conjunction with the lengthening of survival of esophageal cancer patients.
  • The clinical symptoms related to tumors are associated with short-term survival, whereas the cancers detected by routine endoscopy screening have occasional long-term survival.
  • Gastrectomy is proposed for surgical treatment but the operating procedure is complex with a high morbidity rate.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069598.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Inoue T, Ohyama C, Hatakeyama S, Horikawa Y, Togashi H, Tsuchiya N, Matsuura S, Satoh S, Sato K, Habuchi T: [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma]. Hinyokika Kiyo; 2005 Mar;51(3):165-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
  • Immunochemotherapy consisting of interferon-alpha (IFN-alpha), interleukin-2 (IL-2), and gemcitabine (GEM) for metastatic renal cell carcinoma.
  • A partial response maintained for 15 months, was obtained in one case resistant to IFN-alpha and IL-2 of para-aortic lymph node metastases (case 1).
  • A minor response with 30% reduction of lung metastasis was obtained in one IFN-alpha resistant case, and the duration was 6 months (case 2).
  • In one case, in contra-lateral renal metastasis, no disease progression was obtained for 6 months (case 3).
  • One case with resistance to IFN-alpha and IL-2, and who had preoperative abnormalities of corrected serum calcium, serum c-reactive protein and hemoglobin, had progressive disease and died of cancer after 6 months (case 4).
  • Although the response duration was short, the combination immunochemotherapy consisting of IFN-alpha, IL-2 and GEM may be a promising salvage regimen for the patients with metastatic renal cell carcinoma.
  • [MeSH-minor] Adult. Drug Administration Schedule. Female. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852669.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Kunze B, Bürkle S, Kluba T: Multifocal osteosarcoma in childhood. Chir Organi Mov; 2009 May;93(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcoma is one of the most common primary malignant bone tumours in childhood, mainly affecting the metaphysis of long extremity bones.
  • In rare cases, patients present at time of diagnosis with multiple bone lesions, sometimes in the absence of pulmonary metastases.
  • The pathology pattern of these multifocal osteosarcomas occurring with a rare incidence of 0.5-4% is not yet clear, and in spite of investigations in diagnosis and therapy, the prognosis is still poor.
  • The age of both children at the time of tumour detection was 14 years.
  • A synchronous or metachronous occurrence of multiple bone lesions, initially in the absence of pulmonary metastases was seen.
  • Tumour response to chemotherapy was good in one patient, and poor in the other case.
  • The disease-free time was 1 year before detection of pulmonary metastases or relapse.
  • Nevertheless, the survival time is still short and seems to be correlated with the initial histological tumour response to chemotherapy.
  • [MeSH-minor] Adolescent. Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Fatal Outcome. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / surgery. Humans. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Neoadjuvant Therapy. Prognosis. Prostheses and Implants. Respiratory Insufficiency / etiology. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2006 Aug;88(8):1071-5 [16877608.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):864-6 [8922204.001]
  • [Cites] Radiology. 1990 Apr;175(1):233-9 [2315487.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):976-82 [18213710.001]
  • [Cites] Prog Clin Cancer. 1967;3:1-18 [4966305.001]
  • [Cites] Cancer. 1969 Nov;24(5):923-31 [5260741.001]
  • [Cites] J Natl Cancer Inst. 1977 Feb;58(2):205-7 [264592.001]
  • [Cites] Sarcoma. 2004;8(1):13-8 [18521388.001]
  • [Cites] J Bone Joint Surg Am. 1973 Apr;55(3):595-605 [4512956.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):673-9 [18507006.001]
  • [Cites] Med Pediatr Oncol. 1993;21(2):111-6 [8433676.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):701-9 [18245529.001]
  • [Cites] Orphanet J Rare Dis. 2007 Jan 23;2:6 [17244349.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):78-82 [18307025.001]
  • (PMID = 19711159.001).
  • [ISSN] 1973-2538
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Tas F, Kurul S, Camlica H, Topuz E: Malignant melanoma in Turkey: a single institution's experience on 475 cases. Jpn J Clin Oncol; 2006 Dec;36(12):794-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in Turkey: a single institution's experience on 475 cases.
  • METHODS: The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry.
  • RESULTS: Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I-II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively.
  • The Breslow thickness distributed equally, whereas tumor invasion aggregated mainly at Clark level III and IV.
  • In metastatic patients, two thirds had distant metastases including lung metastases and half of them had single metastatic region.
  • Nodular histology subtype, deeper Breslow tumor depth, extensive invasion, presence of ulceration, advanced stage, presence of relapse, being male and elderly patient, presence of visceral recurrence, and high mitotic activity were found to be associated with poor prognosis for overall survival in localized disease.
  • The median survival of metastatic patients was 9.9 months and 1-year overall survival rate was 32.7%.
  • Unresponsiveness to chemotherapy, visceral metastasis, multiple metastases and not given chemotherapy were the poor prognostic factors for overall survival.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age of Onset. Aged. Aged, 80 and over. Female. Humans. Incidence. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival Rate. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060409.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Nadu A, Laufer M, Winkler H, Kleinmann N, Ramon J: [The laparoscopic approach to renal tumors outcome of 121 laparoscopic radical and partial nephrectomy procedures]. Harefuah; 2005 Sep;144(9):609-12, 679
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: We present and review a single center experience with laparoscopic renal surgery for renal cancer including laparoscopic radical and partial nephrectomy.
  • The pathological examination demonstrated renal cell carcinoma in 109 cases, oncocytoma in 6 cases, angiomyolipoma in 2 cases, sarcoma of the kidney and metastasis from lung cancer in one case each and a hemorrhagic cyst in one case.
  • In all patients who underwent radical nephrectomy negative surgical margins were obtained, in three patients after partial nephrectomy the surgical margins were focally involved by tumor.
  • The mean tumor size was 5.1 cm and 3.1 cm after radical or partial nephrectomy respectively.
  • CONCLUSIONS: The laparoscopic approach to kidney cancer seems to be safe and oncologically sound.
  • The low morbidity rate together with the inherent advantages of laparoscopic surgery make this approach attractive and we believe it should be considered the new standard of care for renal cancer.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218528.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


17. Henderson RH, Cohen VM, Rath PP, Luthert P, Hungerford JL: Histopathologically proven mucinous cystadenocarcinoma metastatic to the choroid. Retin Cases Brief Rep; 2010;4(2):181-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologically proven mucinous cystadenocarcinoma metastatic to the choroid.
  • PURPOSE: To report the first case of conventional transcleral choroidal biopsy in the diagnosis of ovarian carcinoma metastatic to the choroid and to summarize the published cases of ovarian carcinoma metastatic to the choroid.
  • Transcleral choroidal biopsy allowed the diagnosis of metastatic mucinous cystadenocarcinoma of the ovary.
  • Choroidal metastases are not associated with central nervous system involvement; however, investigations may reveal distal boney or pulmonary metastases.
  • CONCLUSION: Ovarian carcinoma rarely metastases to the choroid and unlike breast carcinoma, concurrent central nervous system disease has not been reported.
  • When systemic investigations fail to reveal active intraperitoneal disease or distal metastases, the clinician should consider referral to an ocular oncology center for a choroidal biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25390397.001).
  • [ISSN] 1935-1089
  • [Journal-full-title] Retinal cases & brief reports
  • [ISO-abbreviation] Retin Cases Brief Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
  • Increased expression of urokinase plasminogen activator (uPA) has been reported in various malignancies including prostate cancer.
  • However, the mechanism by which uPA is abnormally expressed in prostate cancer remains elusive.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • This aberrant expression is associated with cancer-linked demethylation of the uPA promoter.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


19. Kim AW, Faber LP, Warren WH, Saclarides TJ, Carhill AA, Basu S, Choh MS, Liptay MJ: Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery; 2008 Oct;144(4):712-7; discussion 717-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial.
  • BACKGROUND: Initial pulmonary metastatectomy for limited colorectal carcinoma metastases is associated with improved survival.
  • The purpose of this study is to clarify the role of repeat pulmonary resection for metastatic colorectal carcinoma.
  • METHODS: A retrospective study was performed using patients who underwent pulmonary metastatectomy for colorectal carcinoma at a single academic institution between January 1, 1985, and December 31, 2007.
  • Sex, age at colorectal operation, colorectal TNM stage, and operative procedures for pulmonary metastases were recorded.
  • Intervals between the original colorectal operation and thoracic operation and between the first pulmonary metastatectomy and repeat thoracic interventions were calculated.
  • RESULTS: A total of 69 patients were identified as having undergone at least 1 pulmonary metastatectomy.
  • There were 32 female and 37 male patients with a mean age of 57 +/- 11 years.
  • The median disease-free interval from original colorectal operation to first pulmonary metastatectomy for all the patients was 27 months.
  • A total of 125 pulmonary resections were performed: 64 wedge resections, 27 segmentectomies, 30 lobectomies, and 4 pneumonectomies.
  • From the initial pulmonary metastatectomy, the 5-year survival for all patients was 25% (median, 36 months).
  • CONCLUSIONS: Patients undergoing multiple pulmonary resections have the same survival as patients undergoing a single pulmonary resection for metachronous colorectal carcinoma.
  • These findings indicate pulmonary metastases may be favorably treated with repeat thoracic interventions.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonectomy / methods. Pneumonectomy / statistics & numerical data. Probability. Prognosis. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847658.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A, Gambhir SS, Cheng Z: Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med; 2009 Oct;50(10):1692-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanin-targeted preclinical PET imaging of melanoma metastasis.
  • Dialkylamino-alkyl-benzamides possess an affinity for melanin, suggesting that labeling of such benzamides with (18)F could potentially produce melanin-targeted PET probes able to identify melanotic melanoma metastases in vivo with high sensitivity and specificity.
  • In vivo, (18)F-FBZA displayed significant tumor uptake; at 2 h, 5.94 +/- 1.83 percentage injected dose (%ID) per gram was observed in B16F10 tumors and only 0.75 +/- 0.09 %ID/g and 0.56 +/- 0.13 %ID/g was observed in amelanotic A375M and U87MG tumors, respectively.
  • Lung uptake was significantly higher in murine lungs bearing melanotic B16F10 pulmonary metastases than in normal murine lungs (P < 0.01).
  • Small-animal PET clearly identified melanotic lesions in both primary and pulmonary metastasis B16F10 tumor models.
  • Coregistered micro-CT with small-animal PET along with biopsies further confirmed the presence of tumor lesions in the mouse lungs.
  • CONCLUSION: (18)F-FBZA specifically targets primary and metastatic melanotic melanoma lesions with high tumor uptake and may have translational potential.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pigment Cell Res. 2000 Aug;13(4):283-93 [10952398.001]
  • [Cites] J Med Chem. 2000 Oct 19;43(21):3913-22 [11052796.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):248-56 [11216523.001]
  • [Cites] J Med Chem. 2001 Sep 13;44(19):3132-40 [11543682.001]
  • [Cites] Melanoma Res. 2002 Apr;12(2):115-21 [11930107.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):683-93 [12209157.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1478-84 [12397467.001]
  • [Cites] J Med Chem. 2002 Dec 19;45(26):5802-5 [12477363.001]
  • [Cites] Mol Imaging. 2003 Jul;2(3):131-7 [14649056.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):1927-32 [14660718.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14865-70 [15469923.001]
  • [Cites] Cancer Res. 1984 Mar;44(3):1128-34 [6318981.001]
  • [Cites] Drug Metab Rev. 1984;15(5-6):1183-212 [6396056.001]
  • [Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]
  • [Cites] Pigment Cell Res. 1989 Jan-Feb;2(1):34-9 [2717528.001]
  • [Cites] J Nucl Med. 1989 Mar;30(3):390-7 [2472474.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1573-80 [1869982.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]
  • [Cites] Biochem J. 1991 Dec 15;280 ( Pt 3):721-5 [1764036.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):806-11 [8496620.001]
  • [Cites] J Nucl Med. 1993 Aug;34(8):1260-6 [8326382.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1741-7 [7965150.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10):1806-10 [7562047.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):127-33 [8998166.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3B):1577-82 [9179197.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4979-86 [15958536.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Apr;21(2):117-29 [16706632.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]
  • [Cites] J Med Chem. 2007 Jul 26;50(15):3561-72 [17602544.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Med Chem. 2008 Jun 12;51(11):3133-44 [18481842.001]
  • [Cites] Bioorg Med Chem. 2008 Aug 15;16(16):7671-90 [18656367.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2373-9 [19293257.001]
  • (PMID = 19759116.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA114747; United States / NCI NIH HHS / CA / R24 CA93862
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Fluorine Radioisotopes; 0 / Melanins; 0 / Receptors, sigma
  • [Other-IDs] NLM/ NIHMS636087; NLM/ PMC4215196
  •  go-up   go-down


21. García-Yuste M, Matilla JM, González-Aragoneses F, Heras F: [Detection of lymph node involvement and surgical treatment of pulmonary neoplastic processes. Current state of diagnostic and therapeutic procedures]. Arch Bronconeumol; 2010 Mar;46 Suppl 1:43-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of lymph node involvement and surgical treatment of pulmonary neoplastic processes. Current state of diagnostic and therapeutic procedures].
  • [Transliterated title] Detección de la afectación ganglionar y tratamiento quirúrgico de los procesos neoplásicos pulmonares. Estado actual de distintos procederes diagnósticos y terapéuticos.
  • An analysis is made of different publications associated with the surgical staging and treatment of primary and metastasic pulmonary neoplastic processes.
  • Different factors, age, lung function, tumour location and type of sublobar resection, are analysed.
  • Surgical resection is an accepted therapeutic option in the treatment of colorectal cancer lung metastases.
  • Its indication is based on acceptable survival rates and knowledge of the impact of various factors (interval free of disease, number of metastases, presence of liver metastasis, presence of lymph node involvement, or increased pre-operative levels of carcinoembryonic antigen), is analysed in detail.
  • [MeSH-major] Lung Neoplasms / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20353850.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


22. Ishibashi M, Nakayama K, Shamima Y, Katagiri A, Iida K, Nakayama N, Miyazaki K: [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA]. Gan To Kagaku Ryoho; 2008 May;35(5):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It accounts for 0.5% of all uterine corpus malignant tumors and 10% of all malignant non-epithelial tumors.
  • We describe two cases in which patients with metastatic low-grade ESS lesions had prolonged survival with MPA therapy.
  • Case 1 was a 50-year-old woman with a low-grade uterine endometrial stromal tumor who had been operated on at another hospital.
  • She had pelvis metastases with infiltration into the bladder, and pulmonary metastases.
  • We initiated MPA therapy, which resulted in significant improvement in her metastatic lesions.
  • Her cancer recurred with pelvic and paraaortic lymph node metastasis.
  • Her metastases improved, and the patient has continued to survive on MPA therapy alone.
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


23. Khan AA, Tambiah J, Cane P, Lang-Lazdunski L: Prolonged survival in a patient with recurrent pulmonary metastases secondary to mucinous cystadenocarcinoma of the appendix with pseudomyxomatous peritonei. Ann Thorac Surg; 2007 May;83(5):1893-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in a patient with recurrent pulmonary metastases secondary to mucinous cystadenocarcinoma of the appendix with pseudomyxomatous peritonei.
  • We report a 65-year-old man presenting with recurrent pulmonary metastases 20 years after an appendectomy for mucinous cystadenocarcinoma with pseudomyxomatous peritonei.
  • He underwent bilateral staged metastatectomies for metastases 7 years after the diagnosis and further metastasectomy after a recent recurrence.
  • This is a rare case of recurrent pulmonary metastatic mucinous cystadenocarcinoma, and despite poor prognosis and nondefinitive initial treatment, this patient remains alive and well 20 years later.
  • [MeSH-major] Appendiceal Neoplasms / surgery. Cystadenocarcinoma, Mucinous / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462430.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Zhang Y, Ding JA, Xie BX: [Surgical management for pulmonary metastasis]. Zhonghua Zhong Liu Za Zhi; 2005 Mar;27(3):177-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management for pulmonary metastasis].
  • OBJECTIVE: To investigate the indications of resection for lung metastasis, the surgical procedure and factors affecting the survival based on our experience accumulated for 37 years.
  • METHODS: A total of 108 patients with pulmonary metastasis was treated by surgery.
  • Totally 122 operations were performed: partial lung resection 51, segmental lobectomy 7, lobectomy 40, pneumonectomy 15.
  • Solitary lesions, disease-free interval (DFI) > 36 months, absence of extrathoracic disease and "open" thoracotomy were predictors of a longer survival whereas age, gender, symptom and pathology of the primary tumor were found statistically insignificant prognostic factors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Neoplasms / pathology. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Sarcoma / secondary. Sarcoma / surgery. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946572.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Lee WT, Tamai H, Cohen P, Teker AM, Shu S: Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. Arch Otolaryngol Head Neck Surg; 2008 Jun;134(6):608-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids.
  • OBJECTIVE: To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC).
  • DESIGN: Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2(K)) mice.
  • Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy.
  • Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors.
  • Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio.
  • MAIN OUTCOME MEASURES: Tumor size and overall survival.
  • RESULTS: Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls.
  • In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001).
  • Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models.
  • CONCLUSION: Immunotherapy with fused dendritic-tumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Dendritic Cells / immunology. Immunotherapy. Tumor Cells, Cultured / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559727.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Bergamo A, Masi A, Dyson PJ, Sava G: Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol; 2008 Dec;33(6):1281-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.
  • The modulation of the metastatic progression of breast cancer has been evaluated in vitro and in vivo with RAPTA-T, [Ru(eta6-toluene)Cl2(PTA)], an organometallic ruthenium compound.
  • In vitro RAPTA-T inhibits some steps of the metastatic process such as the detachment from the primary tumour, the migration/invasion and the re-adhesion to a new growth substrate.
  • In vivo RAPTA-T selectively reduces the growth of lung metastases, an effect that might be explained by the in vitro activity.
  • The effect on tests requiring the interaction of the tumour cells with extra cellular matrix components, might suggest an interaction with cell surface molecules in the activity of this ruthenium compound.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Cell Adhesion / drug effects. Cell Movement / drug effects. Lung Neoplasms / prevention & control. Organometallic Compounds / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / drug effects. Collagen Type IV / metabolism. Female. Fibronectins / metabolism. Humans. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Inbred CBA. Neoplasm Invasiveness. Polylysine / metabolism. Time Factors


27. Corpa-Rodríguez ME, Mayoralas-Alises S, García-Sánchez J, Gil-Alonso JL, Díaz-Agero P, Casillas-Pajuelo M: [Postoperative course in 7 cases of primary sarcoma of the lung]. Arch Bronconeumol; 2005 Nov;41(11):634-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative course in 7 cases of primary sarcoma of the lung].
  • [Transliterated title] Evolución posquirúrgica de 7 sarcomas pulmonares primitivos.
  • Unlike lung metastases of extrapulmonary sarcomas, primary sarcoma of the lung is very rare.
  • Preoperative histologic diagnosis was correct for 2 patients.
  • Histology revealed 4 cases of malignant fibrous histiocytoma, 1 angiosarcoma, 1 osteogenic sarcoma, and 1 undifferentiated sarcoma.
  • Enlarged lymph nodes removed during surgery were tumor free.
  • One patient has a recurrent lymph node tumor in a single lung.
  • In conclusion, surgical treatment of primary sarcoma of the lung can achieve good survival.
  • [MeSH-major] Lung Neoplasms / surgery. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324603.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


28. Chojniak R, Yu LS, Younes RN: Response to chemotherapy in patients with lung metastases: how many nodules should be measured? Cancer Imaging; 2006;6:107-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to chemotherapy in patients with lung metastases: how many nodules should be measured?
  • This study evaluates intra-individual variation in response to chemotherapy in patients with multiple lung metastases.
  • METHODS: We prospectively studied chest CT images of patients with solid tumors and pulmonary metastases under systemic chemotherapy being evaluated for tumor response.
  • The response of 566 pulmonary nodules in 41 evaluations was determined by both WHO and RECIST criteria in order to determine intra-individual tumor response variation.
  • RESULTS: There was almost perfect agreement between the WHO and the RECIST criteria for the evaluation of tumor response.
  • High intra-individual variability of tumor response was observed in a significant proportion of the evaluations.
  • A mean of 35% of the total number of nodules of a patient have a response evaluation different from that calculated with all the nodules together.
  • CONCLUSIONS: Intra-individual variation in tumor response of pulmonary metastases is elevated in some patients.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Comput Assist Tomogr. 2003 May-Jun;27(3):380-4 [12794603.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2574-82 [12829678.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):374-7 [12902889.001]
  • [Cites] JAMA. 1965 Nov 29;194(9):973-8 [5897966.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):948-56 [16087090.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3):207-21 [4048964.001]
  • [Cites] Radiology. 1991 Jul;180(1):1-12 [2052672.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3507-14 [9396404.001]
  • [Cites] Acad Radiol. 2004 Dec;11(12):1355-60 [15596373.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • (PMID = 16861137.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1693775
  •  go-up   go-down


29. Jayaprasad N, Anees T, Bijin T, Madhusoodanan S: Severe hypoglycemia due to poorly differentiated hepatocellular carcinoma. J Assoc Physicians India; 2006 May;54:413-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of poorly differentiated hepatoma with multiple lung metastases presenting with recurrent hypoglycemic seizures as the only manifestation four months before the diagnosis of the tumour.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Hypoglycemia / etiology. Liver Neoplasms / pathology. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Humans. Lung Neoplasms / secondary. Male. Middle Aged

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909744.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


30. Tori M, Akamatsu H, Ueshima S, Tsujimoto M, Nakahara M: Recurrent Ascending Colon Cancer Manifesting as Inferior Vena cava Thrombus. Case Rep Gastroenterol; 2008;2(2):181-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent Ascending Colon Cancer Manifesting as Inferior Vena cava Thrombus.
  • We report an extremely rare case of recurrent ascending colon cancer manifesting as inferior vena cava (IVC) thrombus.
  • A 77-year-old woman previously diagnosed with ascending colon cancer underwent right hemicolectomy with lymph node dissection.
  • Though the tumor invaded the retroperitoneum and involved the right ovarian artery and vein, curative operation was performed.
  • Two and a half years later, tumor thrombus in the IVC extending into the right atrium was incidentally found and diagnosed as recurrence of colon cancer by biopsy.
  • RF-induced hyperthermia using 5-FU and CDDP i.v. was immediately performed, but she died after 6 months because of multiple liver and pulmonary metastases.
  • In treating colon cancers invading the retroperitoneum, it should be recalled that some cases recur as tumor thrombus in the IVC and that close follow-up is therefore necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):472-4 [16012302.001]
  • [Cites] Ann Vasc Surg. 2005 Jul;19(4):522-8 [15968492.001]
  • [Cites] Urology. 2005 Aug;66(2):266-70 [16098354.001]
  • [Cites] BJU Int. 2005 Oct;96(6):815-8 [16153208.001]
  • [Cites] Clin Imaging. 2007 Jan-Feb;31(1):44-6 [17189847.001]
  • [Cites] Ann Nucl Med. 2007 Jun;21(3):185-8 [17561590.001]
  • [Cites] J Vasc Surg. 1991 Apr;13(4):506-9 [2010925.001]
  • [Cites] J Urol. 1988 Jun;139(6):1166-72 [3373579.001]
  • [Cites] Ann Surg. 1984 Jun;199(6):656-68 [6732311.001]
  • [Cites] BJU Int. 2005 Aug;96(3):291-5 [16042716.001]
  • [Cites] Arch Ital Urol Androl. 2005 Mar;77(1):84-6 [15906802.001]
  • [Cites] J Urol. 2005 Jun;173(6):1897-902 [15879771.001]
  • [Cites] Eur Urol. 2005 Mar;47(3):352-6 [15716200.001]
  • [Cites] Int J Urol. 2004 Apr;11(4):239-42 [15028104.001]
  • (PMID = 21327176.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3037984
  • [Keywords] NOTNLM ; Inferior vena cava / Recurrent colon cancer / Tumor thrombus
  •  go-up   go-down


31. Matsumoto S, Tanaka F, Sato K, Kimura S, Maekawa T, Hasegawa S, Wada H: Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma. Lung Cancer; 2009 Oct;66(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma.
  • OBJECTIVES: The prognosis of patients with malignant pleural effusion (MPE) is poor.
  • METHODS: First, mice without pleural metastasis of lung carcinoma were given a single injection of docetaxel (Taxotere) in the thoracic cavity.
  • Finally, A549 lung cancer cells transfected with luciferase gene (A549-Luc) were injected into the intrapleural cavity of the mouse.
  • When pleural metastasis was established, we started repeated intrapleural administration of docetaxel (once a week for 8 weeks).
  • All bioluminescent data were collected and analysed with a Xenogen IVIS system. RESULTS:.
  • After confirmation of tumor formation, repeated injections of docetaxel were administered.
  • (1) We established a MPE model. (2) IVIS facilitates faster and more accurate counting of disseminated foci in the pleura (as compared to the previous standard of measuring body weight changes) in a cancerous pleuritis model. (3) Repeated intrapleural administration of docetaxel is effective.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Drug Monitoring / methods. Lung Neoplasms / drug therapy. Pleural Effusion, Malignant / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Female. Humans. Injections. Luciferases, Firefly / analysis. Luciferases, Firefly / genetics. Mice. Mice, Inbred BALB C. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178977.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; EC 1.13.12.7 / Luciferases, Firefly
  •  go-up   go-down


32. Li Z, Zhou Z, Welch DR, Donahue HJ: Expressing connexin 43 in breast cancer cells reduces their metastasis to lungs. Clin Exp Metastasis; 2008;25(8):893-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expressing connexin 43 in breast cancer cells reduces their metastasis to lungs.
  • Recently the concept that gap junctions play a role in cancer cell metastasis has emerged.
  • To examine this issue a metastatic breast cancer cell line, MDA-MB-435, was stably transfected with human Cx43 cDNA.
  • However, forced expression of Cx43 decreased the growth of MDA-MB-435 cells, decreased expression of N-cadherin, which is frequently associated with an aggressive phenotype, and increased MDA-MB-435 sensitivity to apoptosis.
  • More importantly, there were fewer lung metastases in mice injected with 435/Cx43(+) cells relative to mice injected with 435/hy.
  • These results suggest that expressing Cx43 in breast cancer cells decreases their metastatic potential through a mechanism independent of gap junctional communication but, rather, related to N-cadherin expression and apoptosis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):29132-8 [12042301.001]
  • [Cites] Cell Commun Adhes. 2001;8(4-6):377-82 [12064622.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):450-61 [12761879.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 4;306(3):746-9 [12810082.001]
  • [Cites] Cell Commun Adhes. 2003 Jul-Dec;10(4-6):445-50 [14681055.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):693-7 [15252837.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):631-44 [10545506.001]
  • [Cites] Bone. 1999 Dec;25(6):661-6 [10593410.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):779-90 [10684258.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):505-13 [10698520.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1189-97 [10791993.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2764-9 [10850410.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1765-7 [11280719.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):130-8 [11279616.001]
  • [Cites] Mol Carcinog. 2001 Nov;32(3):128-38 [11746825.001]
  • [Cites] Nature. 1966 Mar 19;209(5029):1248-9 [5956321.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jan;85(2):473-6 [3422438.001]
  • [Cites] J Cell Biol. 1991 Aug;114(3):545-55 [1650371.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 1):G911-6 [8238521.001]
  • [Cites] J Bone Miner Res. 1995 Feb;10(2):178-86 [7754797.001]
  • [Cites] Mutat Res. 1995 Dec;333(1-2):181-8 [8538626.001]
  • [Cites] Cell Growth Differ. 1996 Jul;7(7):861-70 [8809403.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):272-306 [9174129.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2043-50 [9395200.001]
  • [Cites] Cell Biol Int. 1997 Dec;21(12):833-43 [9812347.001]
  • [Cites] Dev Genet. 1999;24(1-2):91-110 [10079514.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4104-10 [10463615.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):325-9 [16012710.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Apr;290(4):C1248-55 [16319124.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1117-23 [16596172.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):13-9 [17004106.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):1-4 [17960586.001]
  • [Cites] J Membr Biol. 2007 Aug;218(1-3):107-21 [17661126.001]
  • [Cites] J Cell Biochem. 2008 Jan 1;103(1):30-41 [17471510.001]
  • [Cites] Clin Exp Metastasis. 2008;25(3):265-72 [18193170.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32905-14 [12095980.001]
  • (PMID = 18839320.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087728-07; United States / NCI NIH HHS / CA / R01 CA087728-04; United States / NIA NIH HHS / AG / AG13087; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / CA087728-06; United States / NCI NIH HHS / CA / CA87228; United States / NIA NIH HHS / AG / R01 AG013087; United States / NCI NIH HHS / CA / R01 CA087728-08; United States / NCI NIH HHS / CA / CA087728-05A1; United States / NCI NIH HHS / CA / CA087728-04; United States / NCI NIH HHS / CA / R01 CA087728-06; United States / NCI NIH HHS / CA / R01 CA090991; United States / NCI NIH HHS / CA / R01 CA087728-05A1; United States / NCI NIH HHS / CA / CA90991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Connexin 43; 0 / Connexins; 0 / RNA, Messenger; 0 / connexin 32; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS134615; NLM/ PMC2754227
  •  go-up   go-down


33. Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB: Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer; 2010;10:175
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid.
  • BACKGROUND: Advanced cancer is a multifactorial disease that demands treatments targeting multiple cellular pathways.
  • Chinese herbal cocktail which contains various phytochemicals may target multiple dys-regulated pathways in cancer cells and thus may provide an alternative/complementary way to treat cancers.
  • Previously we reported that the Chinese herbal cocktail Tien-Hsien Liguid (THL) can specifically induce apoptosis in various cancer cells and have immuno-modulating activity.
  • In this study, we further evaluated the anti-metastatic, anti-angiogenic and anti-tumor activities of THL with a series of in vitro and in vivo experiments.
  • METHODS: The migration and invasion of cancer cells and endothelial cells was determined by Boyden chamber transwell assays.
  • The effect of THL on pulmonary metastasis was done by injecting CT-26 colon cancer cells intravenously to syngenic mice.
  • The in vivo anti-tumor effect of THL was determined by a human MDA-MB-231 breast cancer xenograft model.
  • RESULTS: THL inhibited the migration and invasion ability of various cancer cells in vitro, decreased the secretion of MMP-2, MMP-9, and uPA and the activity of ERK1/2 in cancer cells, and suppressed pulmonary metastasis of CT-26 cancer cells in syngenic mice.
  • Besides its inhibitory effect on endothelial cells, THL inhibited hypoxia-induced HIF-1alpha and vascular endothelial growth factor-A expression in cancer cells.
  • Finally, our results show that THL inhibited the growth of human MDA-MB-231 breast cancer xenografts in NOD-SCID mice.
  • This suppression of tumor growth was associated with decreased microvessel formation and increased apoptosis caused by THL.
  • CONCLUSION: Our data demonstrate that THL had broad-spectra anti-cancer activities and merits further evaluation for its use in cancer therapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / drug therapy. Cell Movement / drug effects. Colonic Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Lung Neoplasms / prevention & control. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Endothelial Cells / drug effects. Endothelial Cells / pathology. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Inbred BALB C. Mice, Inbred NOD. Mice, SCID. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Neoplasm Invasiveness. Time Factors. Tumor Burden. Urokinase-Type Plasminogen Activator / metabolism. Vascular Endothelial Growth Factor A / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5847-57 [16740724.001]
  • [Cites] Nat Med. 2006 Aug;12(8):895-904 [16892035.001]
  • [Cites] Nat Cell Biol. 1999 May;1(1):60-7 [10559866.001]
  • [Cites] Cancer Lett. 2000 Mar 13;150(1):41-8 [10755385.001]
  • [Cites] Cancer Biother Radiopharm. 1996 Feb;11(1):51-6 [10851520.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):565-76 [10880039.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):649-54 [10919709.001]
  • [Cites] Cancer Invest. 1999;17(1):30-5 [10999046.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Biochem J. 2001 May 1;355(Pt 3):653-61 [11311127.001]
  • [Cites] J Korean Med Sci. 2001 Dec;16 Suppl:S28-37 [11748374.001]
  • [Cites] J Agric Food Chem. 2002 Feb 13;50(4):677-84 [11829627.001]
  • [Cites] Planta Med. 2002 Feb;68(2):119-22 [11859460.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Apr;49(4):261-6 [11914903.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20631-9 [11904305.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):23-30 [12049811.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5204-9 [12234985.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Cancer Invest. 2002;20(7-8):1069-79 [12449740.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):75-80 [12497209.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6):531-45 [12516036.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2455-63 [16777983.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1391-7 [17487396.001]
  • [Cites] J Mol Med (Berl). 2007 Dec;85(12):1301-7 [18026916.001]
  • [Cites] J Pathol. 2008 Feb;214(3):283-93 [18095256.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2008 Mar;33(5):549-52 [18536381.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):4053-8 [12553032.001]
  • [Cites] Zhong Yao Cai. 1999 Jul;22(7):351-3 [12571931.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):670-3 [12679907.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):269-85 [14619979.001]
  • [Cites] Curr Pharm Des. 2004;10(1):39-49 [14754404.001]
  • [Cites] Oncogene. 2004 May 6;23(21):3841-50 [15021904.001]
  • [Cites] J Herb Pharmacother. 2004;4(1):21-33 [15273074.001]
  • [Cites] Am J Chin Med. 2004;32(2):221-34 [15315260.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Jpn J Exp Med. 1989 Aug;59(4):157-61 [2601113.001]
  • [Cites] Adv Cancer Res. 1990;54:159-211 [1688681.001]
  • [Cites] Nutr Cancer. 1991;15(3-4):187-93 [1907733.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1992 Jan;40(1):143-7 [1576664.001]
  • [Cites] J Cell Physiol. 1992 Dec;153(3):614-25 [1280280.001]
  • [Cites] Stem Cells. 1994 Jan;12(1):53-63 [8142920.001]
  • [Cites] Am J Chin Med. 1994;22(1):19-28 [8030616.001]
  • [Cites] Biol Pharm Bull. 1994 May;17(5):635-9 [7522731.001]
  • [Cites] Cancer Invest. 1994;12(6):611-5 [7994596.001]
  • [Cites] Cancer Biother. 1994 Summer;9(2):153-61 [7812364.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1995 Feb;17(1):69-79 [7759776.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):19761-6 [7544346.001]
  • [Cites] Biol Pharm Bull. 1995 Oct;18(10):1382-6 [8593441.001]
  • [Cites] Microvasc Res. 1998 Jan;55(1):29-42 [9473407.001]
  • [Cites] Planta Med. 1999 Feb;65(1):35-8 [10083842.001]
  • [Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]
  • [Cites] Jpn J Pharmacol. 1999 Mar;79(3):335-41 [10230862.001]
  • [Cites] Phytochemistry. 1999 Aug;51(7):891-8 [10423860.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1030:208-18 [15659800.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):741-51 [15661802.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12503-16 [15611127.001]
  • [Cites] J Altern Complement Med. 2005 Apr;11(2):245-56 [15865490.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1755(1):37-69 [15907591.001]
  • [Cites] Biotechnol Appl Biochem. 2005 Aug;42(Pt 1):9-15 [15574120.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6682-9 [16170176.001]
  • [Cites] Am J Chin Med. 2005;33(4):559-71 [16173530.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • (PMID = 20429953.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / tien-hsien liquid; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2880989
  •  go-up   go-down


34. Farhat F, Fakhruddine N: A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman. Eur J Gynaecol Oncol; 2008;29(1):95-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman.
  • PURPOSE & METHODS: We report a case of a 42-year-old multigravida, premenopausal woman with breast carcinoma, who presented after four years of use of adjuvant tamoxifen with synchronous liver, bone, and lung metastasis of breast cancer with müllerian adenosarcoma.
  • RESULTS: Immunohistochemical stains on the uterine tumor for estrogen and progesterone receptors showed positivity for both epithelial and stromal cells, actin, and desmin while the proliferative index (MIB-1) showed positivity for stromal cells only.
  • She died 14 months after her relapse because of progressive disease (cerebral, bone, liver and lung metastases).
  • Moreover, it is one of the rare cases occurring in a premenopausal woman since all except two cases were postmenopausal.
  • [MeSH-major] Adenosarcoma / pathology. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / complications. Tamoxifen / adverse effects. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Metastasis. Premenopause. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386476.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 12
  •  go-up   go-down


35. Takami M, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Sakamoto H, Yamamoto T: [A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel]. Gan To Kagaku Ryoho; 2007 Mar;34(3):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell carcinoma of the endometrium is a very rare and highly malignant neoplasm that accounts for less than 5% of endometrial carcinoma.
  • We report the case of a 62-year-old woman who had Stage IVb advanced clear cell carcinoma of the endometrium with multiple lung metastases.
  • After 3 courses of chemotherapy, the uterine tumor was obviously reduced, and lung metastases had disappeared.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Hysterotomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


36. Shido Y, Nishida Y, Suzuki Y, Kobayashi T, Ishiguro N: Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model. J Bone Joint Surg Br; 2010 Apr;92(4):580-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model.
  • We undertook a study of the anti-tumour effects of hyperthermia, delivered via magnetite cationic liposomes (MCLs), on local tumours and lung metastases in a mouse model of osteosarcoma.
  • The distribution of MCLs and local and lung metastases was evaluated histologically.
  • The weight and volume of local tumours and the number of lung metastases were determined.
  • Hyperthermia using MCLs effectively heated the targeted tumour to 45 degrees C.
  • The mean weight of the local tumour was significantly suppressed in the hyperthermia group (p = 0.013).
  • The mice subjected to hyperthermia had significantly fewer lung metastases than the control mice (p = 0.005).
  • The results demonstrate a significant effect of hyperthermia on local tumours and reduces their potential to metastasise to the lung.
  • [MeSH-minor] Animals. HSP70 Heat-Shock Proteins / metabolism. Liposomes. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Male. Metal Nanoparticles / administration & dosage. Mice. Mice, Inbred C3H. Necrosis. Skin Temperature

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357339.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / Liposomes; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


37. Chelli D, Dimassi K, Bouaziz M, Ghaffari C, Zouaoui B, Sfar E, Chelli H, Chennoufi MB: [Imaging of gestational trophoblastic disease]. J Gynecol Obstet Biol Reprod (Paris); 2008 Oct;37(6):559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Trophoblastic diseases correspond to a very heterogeneous group.
  • PATIENTS AND METHODS: Retrospective study from 1995 to 2008, including all patients with a gestational throphoblastic disease in our department.
  • RESULTS: Seventy-four cases were identified with 58 molar pregnancies, 14 trophoblastic tumors and two cases of hydatiform mole coexistent with a twin live fetus.
  • It was sharply more important in case of a complete mole with a detection rate of 96.15% against 28% in case of partial mole.
  • Four patients presented with lung metastases.
  • DISCUSSION AND CONCLUSION: Ultrasound is of high-performance in the positive diagnosis of complete moles.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis. Ultrasonography, Prenatal
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Hydatidiform Mole / diagnosis. Hysterectomy. Magnetic Resonance Imaging. Middle Aged. Pregnancy. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome. Trophoblastic Neoplasms / diagnosis. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657917.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J, Muller WJ, Oshima RG, Feng GS: Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene; 2007 Jul 26;26(34):4951-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Gab2 in mammary tumorigenesis and metastasis.
  • Overexpression of the adaptor/scaffolding protein Gab2 has been detected in primary human breast cancer cells and cell lines, although its functional significance in breast carcinogenesis is not fully understood.
  • Here, we show a requirement for Gab2 in promoting mammary tumor metastasis.
  • Notably, ablation of Gab2 severely suppressed lung metastasis.
  • Gab2-deficient cancer cells displayed normal Akt activities, and their proliferative rate in vitro was similar to control cells.
  • However, Gab2(-/-) cancer cells exhibited decreased migration and impaired Erk activation, and the defects were rescued by re-introduction of Gab2 into Gab2(-/-) cells.
  • These findings suggest that although Gab2 overexpression may confer growth advantage to tumor cells, the functional requirement for Gab2 in mammary tumor initiation/growth may be dispensable, and that Gab2 may have a prominent role in promoting mammary tumor metastasis.
  • [MeSH-minor] Animals. Cell Movement. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Genes, erbB-2. Lung Neoplasms / secondary. Mice. Mice, Knockout. Neoplasm Invasiveness


39. Olezac AS, Papanikolaou I, Bengrine-Lefevre L, Chouaid C: [Choriocarcinoma with pulmonary metastasis: diagnosis and treatment]. Rev Mal Respir; 2009 Sep;26(7):769-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choriocarcinoma with pulmonary metastasis: diagnosis and treatment].
  • INTRODUCTION: Choriocarcinoma is a rare tumour which results from the anarchic proliferation of a gonadic or extra gonadic germinal cell.
  • CASE REPORT: A 45 year old pre menopausal woman of African origin presented with a persistent cough and deterioration of general status.
  • Choriocarcinoma, suspected in the presence of an elevated ssHCG without a gravid uterus, was confirmed by biopsy excision of a haemorrhagic cutaneous lesion of the scalp.
  • [MeSH-major] Choriocarcinoma. Lung Neoplasms / secondary
  • [MeSH-minor] Antimetabolites, Antineoplastic. Biopsy. Choriocarcinoma, Non-gestational / diagnosis. Chorionic Gonadotropin / blood. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Methotrexate / therapeutic use. Middle Aged. Pancreatic Neoplasms / secondary. Prognosis. Radiography, Thoracic. Remission Induction. Scalp / pathology. Skin / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953019.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


40. Murai R, Yoshida Y, Muraguchi T, Nishimoto E, Morioka Y, Kitayama H, Kondoh S, Kawazoe Y, Hiraoka M, Uesugi M, Noda M: A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget; 2010 Aug;1(4):252-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs.
  • Forced expression of RECK in cancer cells suppresses tumor angiogenesis, invasion, and metastasis in xenograft models.
  • RECK is therefore a promising marker for benignancy and a potential effector in cancer therapy.
  • Four selected compounds up-regulated endogenous RECK protein in several human cancer cell lines.
  • The top-ranking compound, disulfiram, strongly suppressed spontaneous lung-metastasis of human fibrosarcoma cells in nude mice.
  • Our data demonstrate the value of this screen in discovering effective cancer therapeutics.
  • [MeSH-minor] Alkaline Phosphatase / genetics. Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Disulfiram / pharmacology. Doxycycline / pharmacology. Drug Discovery. Gene Expression Regulation, Neoplastic. Humans. Immunoblotting. Mice. Neoplasm Metastasis. Prognosis. Proto-Oncogene Proteins p21(ras) / genetics. Rats

  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Hazardous Substances Data Bank. DISULFIRAM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3069-72 [12810630.001]
  • [Cites] Mol Pharmacol. 2003 Nov;64(5):1076-84 [14573756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15095-100 [14645705.001]
  • [Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):668-75 [10543990.001]
  • [Cites] Cancer. 1974 Apr;33(4):1027-33 [4132053.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] Science. 1982 May 7;216(4546):637-9 [7071604.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jun;79(11):3527-31 [6954499.001]
  • [Cites] Agents Actions Suppl. 1983;12:14-33 [6573115.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1992;369:15-26 [1471547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13221-6 [9789069.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9062-9 [15604273.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):44-55 [15630443.001]
  • [Cites] Toxicology. 2006 Feb 15;219(1-3):175-86 [16368179.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4718-25 [16377629.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1075-9 [16810242.001]
  • [Cites] Mol Biosyst. 2005 Jul;1(2):127-34 [16880974.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10425-33 [17079463.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40485-92 [17088248.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):169-73 [17233834.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):115-20 [17159925.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):12341-52 [17329256.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1659-65 [17725805.001]
  • [Cites] J Biochem Mol Biol. 2007 Nov 30;40(6):1069-76 [18047805.001]
  • [Cites] Mol Interv. 2008 Feb;8(1):36-49 [18332483.001]
  • [Cites] Pharmacol Ther. 2008 Apr;118(1):18-35 [18374420.001]
  • [Cites] Expert Opin Ther Targets. 2008 Jun;12(6):739-48 [18479220.001]
  • [Cites] J Biol Chem. 2009 Feb 6;284(6):3461-9 [19022775.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1502-8 [19208844.001]
  • [Cites] Oncogene. 2009 Mar 19;28(11):1454-64 [19169281.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):265-73 [19262571.001]
  • [Cites] Arch Toxicol. 2009 Jun;83(6):571-80 [18754103.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jul;8(7):579-91 [19478820.001]
  • [Cites] Cancer Sci. 2009 Jul;100(7):1166-72 [19432904.001]
  • [Cites] Jpn J Cancer Res. 1999 Oct;90(10):1139-45 [10595743.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):34-41 [11774241.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Mol Cancer Ther. 2002 Jan;1(3):197-204 [12467214.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):167-75 [12784995.001]
  • [Cites] Trends Pharmacol Sci. 2009 Oct;30(10):546-56 [19762091.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6070-8 [19789329.001]
  • [Cites] EMBO Mol Med. 2009 Sep;1(6-7):323-37 [20049736.001]
  • [Cites] Lung Cancer. 2010 Jul;69(1):26-32 [19853959.001]
  • [CommentIn] Oncotarget. 2010 Aug;1(4):233-4 [21304173.001]
  • (PMID = 21304177.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GPI-Linked Proteins; 0 / RECK protein, human; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); N12000U13O / Doxycycline; TR3MLJ1UAI / Disulfiram
  • [Other-IDs] NLM/ PMC3248105
  •  go-up   go-down


41. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • A 64-year-old woman was admitted with a complaint of severe abdominal distension.
  • Abdominal computerized tomography revealed a bowel obstruction with tumor and the remarkable small bowel dilation of oral side of tumor.
  • The tumor was found at surgery to be at the ileum 15 cm proximal from the ileocecal region.
  • Peritoneal dissemination was recognized around the ileocecal region, so ileum partial resection was performed for the primary cancer lesion and dissemination region.
  • Pathological diagnosis of the resected specimen was adenocarcinoma with lymph nodes metastasis.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • For lung metastasis, the combination chemotherapy with mFOLFOX6 + bevacizumab was administered.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Combined Modality Therapy. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Ileal Neoplasms / drug therapy. Leucovorin / administration & dosage. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / secondary. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


42. Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, Berditchevski F: Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res; 2010 Jul 15;70(14):6059-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis.
  • Tetraspanin CD151 is associated with laminin-binding integrins and controls tumor cell migration and invasion.
  • By analyzing responses of breast cancer cells to various growth factors, we showed that depletion of CD151 specifically attenuates transforming growth factor beta1 (TGFbeta1)-induced scattering and proliferation of breast cancer cells in three-dimensional Matrigel.
  • Attenuation of TGFbeta1-induced responses correlated with reduced retention in the lung vascular bed, inhibition of pneumocyte-induced scattering of breast cancer cells in three-dimensional Matrigel, and decrease in experimental metastasis to the lungs.
  • These results identify CD151 as a positive regulator of TGFbeta1-initiated signaling and highlight the important role played by this tetraspanin in TGFbeta1-induced breast cancer metastasis.
  • [MeSH-major] Antigens, CD / metabolism. Breast Neoplasms / pathology. Lung Neoplasms / secondary. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Animals. Antigens, CD151. Cell Line, Tumor. Collagen. Drug Combinations. Epithelial Cells / pathology. Female. Humans. Integrins / metabolism. Laminin. Male. Membrane Microdomains. Mice. Mice, Inbred C57BL. Mice, Nude. Neoplasm Metastasis. Proteoglycans. Signal Transduction


43. Kanazawa T, Nokubi M, Takizawa K, Matsuzawa S, Shinnabe A, Mineta H, Iino Y: KIT and platelet-derived growth factor receptor α gene expression in laryngeal small cell carcinoma. J Laryngol Otol; 2010 Dec;124(12):1340-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to further characterise this tumour, with a view to development of new therapeutic approaches, we report the results of KIT gene and platelet-derived growth factor receptor α gene expression analysis, for two extremely rare cases of primary small cell carcinoma of the larynx.
  • RESULTS: We present two patients with laryngeal small cell carcinoma, who died from tumour metastasis to the lungs and brain despite aggressive treatment.
  • [MeSH-minor] Aged. Brain Neoplasms / secondary. Combined Modality Therapy. Fatal Outcome. Gene Expression Profiling. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Molecular Targeted Therapy

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for laryngeal small cell carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20537211.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / platelet-derived growth factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


44. Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, Inman M, Kolb M: VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest; 2009 May;119(5):1298-311
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.
  • Idiopathic pulmonary fibrosis (IPF) can lead to the development of secondary pulmonary hypertension (PH) and ultimately death.
  • In this model, adenoviral delivery of active TGF-beta1 induces pulmonary arterial remodeling, loss of the microvasculature in fibrotic areas, and increased pulmonary arterial pressure (PAP).
  • These data show that experimental pulmonary fibrosis (PF) leads to loss of the microvasculature through increased apoptosis and to remodeling of the pulmonary arteries, with both processes resulting in PH.
  • [MeSH-major] Apoptosis / drug effects. Endothelial Cells / drug effects. Hypertension, Pulmonary / therapy. Idiopathic Pulmonary Fibrosis / therapy. Vascular Endothelial Growth Factor A / therapeutic use
  • [MeSH-minor] Animals. Bronchoalveolar Lavage Fluid / chemistry. Caspase 3 / metabolism. Disease Models, Animal. Eye Proteins / genetics. Eye Proteins / metabolism. Female. Fibroblasts / drug effects. Fibroblasts / metabolism. Gene Expression / genetics. Genetic Therapy. Humans. Lung / metabolism. Lung / pathology. Lung / physiopathology. Microvessels / drug effects. Microvessels / pathology. Models, Biological. Nerve Growth Factors / genetics. Nerve Growth Factors / metabolism. Nitric Oxide Synthase Type III / genetics. Phosphorylation. Pulmonary Artery / metabolism. Pulmonary Artery / pathology. Rats. Rats, Sprague-Dawley. Serpins / genetics. Serpins / metabolism. Serum Albumin / metabolism. Smad2 Protein / metabolism. Transforming Growth Factor beta1 / genetics. Transforming Growth Factor beta1 / metabolism. Transforming Growth Factor beta1 / pharmacology. Vascular Endothelial Growth Factor Receptor-2 / genetics. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Pulmonary Fibrosis.
  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Dec;106(11):1311-9 [11104784.001]
  • [Cites] FASEB J. 2001 Feb;15(2):427-38 [11156958.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1327-34 [11350814.001]
  • [Cites] Dev Dyn. 2001 Jul;221(3):289-301 [11458389.001]
  • [Cites] N Engl J Med. 2001 Aug 16;345(7):517-25 [11519507.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):291-9 [11531144.001]
  • [Cites] J Am Soc Nephrol. 2001 Oct;12(10):2029-39 [11562401.001]
  • [Cites] Circulation. 2001 Oct 30;104(18):2242-8 [11684638.001]
  • [Cites] J Pathol. 2002 Feb;196(2):220-7 [11793374.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45400-7 [12237317.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G143-50 [15297261.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Dec 15;170(12):1340-8 [15361368.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98 [15563636.001]
  • [Cites] Pediatr Int. 2005 Jun;47(3):242-7 [15910444.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1224-31 [16002726.001]
  • [Cites] Curr Opin Pulm Med. 2005 Sep;11(5):452-5 [16093821.001]
  • [Cites] Lung. 2005 Jul-Aug;183(4):291-300 [16211465.001]
  • [Cites] Chest. 2005 Dec;128(6 Suppl):616S-617S [16373870.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L209-21 [16403941.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3604-13 [16339148.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L661-L673 [16227320.001]
  • [Cites] Chest. 2006 Mar;129(3):746-52 [16537877.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):61-71 [16816361.001]
  • [Cites] Dev Cell. 2006 Jul;11(1):81-92 [16824955.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Aug;35(2):182-9 [16543611.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Sep;291(3):L362-8 [16617095.001]
  • [Cites] J Mol Endocrinol. 2006 Aug;37(1):1-12 [16901919.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):549-56 [17332882.001]
  • [Cites] Am J Respir Crit Care Med. 2007 May 1;175(9):875-80 [17255562.001]
  • [Cites] Eur Respir J. 2007 May;29(5):976-85 [17301095.001]
  • [Cites] J Leukoc Biol. 2007 Sep;82(3):449-56 [17550974.001]
  • [Cites] Chest. 2007 Sep;132(3):998-1006 [17873194.001]
  • [Cites] Cardiovasc Res. 2007 Nov 1;76(2):213-23 [17651710.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Dec 1;176(11):1108-19 [17761615.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(3):362-82 [17936056.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Apr 15;177(8):896-905 [18202349.001]
  • [Cites] Am Rev Respir Dis. 1988 Mar;137(3):579-84 [3345039.001]
  • [Cites] J Clin Pathol. 1988 Apr;41(4):467-70 [3366935.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64 [10673212.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Dec;23(6):762-71 [11104729.001]
  • [Cites] Prog Cardiovasc Dis. 2002 Nov-Dec;45(3):173-202 [12525995.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Feb 1;167(3):438-43 [12406847.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Oct 1;168(7):770-8 [12816739.001]
  • [Cites] Circulation. 2004 Jan 20;109(2):159-65 [14734504.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):343-54 [15122348.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Jun 1;169(11):1203-8 [14754760.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Jun 1;169(11):1179-80 [15161610.001]
  • [Cites] Thorax. 2004 Jul;59(7):581-5 [15223865.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 1;170(3):242-51 [15117744.001]
  • [Cites] Respiration. 1983;44(2):118-27 [6836187.001]
  • [Cites] Am J Pathol. 1986 Oct;125(1):97-106 [2430459.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7057-61 [2208173.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):25-31 [1712541.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):6271-4 [8119973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8802-6 [8090727.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 31;796:186-93 [8906225.001]
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):768-76 [9259574.001]
  • [Cites] Mayo Clin Proc. 1998 Nov;73(11):1085-101 [9818046.001]
  • [Cites] Circulation. 1999 Apr 20;99(15):2019-26 [10209007.001]
  • (PMID = 19381013.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Madh2 protein, rat; 0 / Nerve Growth Factors; 0 / Serpins; 0 / Serum Albumin; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta1; 0 / Vascular Endothelial Growth Factor A; 0 / pigment epithelium-derived factor; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.13.39 / Nos3 protein, rat; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2673845
  •  go-up   go-down


45. Felfernig M, Salat A, Kimberger O, Gradisek P, Müller MR, Felfernig D: Preemptive analgesia by lornoxicam--an NSAID--significantly inhibits perioperative platelet aggregation. Eur J Anaesthesiol; 2008 Sep;25(9):726-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent treatment of solitary lung metastasis and denied any antiplatelet medication within the past 2 weeks.
  • [MeSH-minor] Blood Coagulation Tests / statistics & numerical data. Humans. Lung Diseases / blood. Lung Diseases / surgery. Middle Aged. Perioperative Care / methods. Prospective Studies. Solitary Pulmonary Nodule / surgery. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471341.001).
  • [ISSN] 1365-2346
  • [Journal-full-title] European journal of anaesthesiology
  • [ISO-abbreviation] Eur J Anaesthesiol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; ER09126G7A / lornoxicam
  •  go-up   go-down


46. Suster S, Morrison C: Sclerosing poorly differentiated liposarcoma: clinicopathological, immunohistochemical and molecular analysis of a distinct morphological subtype of lipomatous tumour of soft tissue. Histopathology; 2008 Feb;52(3):283-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing poorly differentiated liposarcoma: clinicopathological, immunohistochemical and molecular analysis of a distinct morphological subtype of lipomatous tumour of soft tissue.
  • AIMS: To present eight cases of a distinctive morphological subtype of lipomatous tumour of soft tissue.
  • Four cases arose de novo and four cases presented as local recurrences of previously resected liposarcomas.
  • Three patients died from their tumours from 1 to 6 years after their last surgery with lung metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local. Sclerosis / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269578.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA-Binding Protein FUS; 0 / TLS-CHOP fusion protein, human; 147336-12-7 / Transcription Factor CHOP; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


47. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Herein is reported a case of a 74-year-old woman with a giant malignant SFT in the pelvis.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • Initial chemotherapies failed to control the tumor.
  • This is the first report related to therapeutic remarks on advanced malignant SFT.
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


48. Hashikura Y, Ikegami T, Nakazawa Y, Urata K, Mihara M, Mita A, Sakon M, Miyagawa S, Ikeda S: Domino liver transplantation in living donors. Transplant Proc; 2005 Mar;37(2):1076-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the seven domino recipients, a 64-year-old woman with advanced hepatocellular carcinoma died of lung metastasis.
  • In living donor liver transplantation, because the vessels of the graft from the first donor are not long enough for anastomosis, the hepatic vessels must be left as long as possible when removing the liver from the FAP patients in order to ensure sufficient safety for vascular reconstruction.


49. Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K, van der Laak J, de Waal R, Mulders P, Oosterwijk E, Leenders W: Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol; 2009 Nov;219(3):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma.
  • Tumour metastasis is the result of a complex sequence of events, including migration of tumour cells through stroma, proteolytic degradation of stromal and vessel wall elements, intravasation, transport through the circulation, extravasation and outgrowth at compatible sites in the body (the 'seed and soil' hypothesis).
  • However, the high incidence of metastasis from various tumour types in liver and lung may be explained by a stochastic process as well, based on the anatomical relationship of the primary tumour with the circulation and mechanical entrapment of metastatic tumour cells in capillary beds.
  • We previously reported that constitutive VEGF-A expression in tumour xenografts facilitates this type of metastatic seeding by promoting shedding of multicellular tumour tissue fragments, surrounded by vessel wall elements, into the circulation.
  • After transport through the vena cava, such fragments may be trapped in pulmonary arteries, allowing them to expand to symptomatic lesions.
  • Here we tested whether this process has clinical relevance for clear cell renal cell carcinoma (ccRCC), a prototype tumour in the sense of high constitutive VEGF-A expression.
  • To this end we collected and analysed outflow samples from the renal vein, directly after tumour nephrectomy, in 42 patients diagnosed with ccRCC.
  • Tumour fragments in venous outflow were observed in 33% of ccRCC patients and correlated with the synchronous presence or metachronous development of pulmonary metastases (p < 0.001, Fisher's exact test).
  • In patients with tumours that, in retrospect, were not of the VEGF-A-expressing clear cell type, tumour fragments were never observed in the renal outflow.
  • These data suggest that, in ccRCC, a VEGF-A-induced phenotype promotes a release of tumour cell clusters into the circulation that may contribute to pulmonary metastasis.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Lung Neoplasms / secondary. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism


50. Hirai K, Sano H, Kita K, Mikata K, Ueki T, Fujikawa N, Kitami K, Hirokawa S: [Small cell carcinoma of the bladder: a case report]. Hinyokika Kiyo; 2005 Sep;51(9):635-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old man was referred to our hospital with a complaint of gross hematuria and lower abdominal discomfort.
  • Ultrasonography, magnetic resonance imaging and cystoscopy revealed a nodular invasive tumor in urinary bladder.
  • Computed tomography (CT) before adjuvant chemotherapy revealed tiny lung metastasis in left peripheral lung area.
  • As postoperative adjuvant therapy, 4 courses of chemotherapy (etoposide and calboplatin) were performed with 50 Gy of extra beam radiotherapy to the lung metastasis.
  • Follow up CT revealed disapperance of lung metastasis, and the patient has been free from disease for one year after chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Carcinoma, Transitional Cell / secondary. Cystectomy. Lung Neoplasms / secondary. Neoplasms, Multiple Primary. Urinary Bladder Neoplasms / pathology. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229379.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


51. Sobel KE, Williams JE: Pneumothorax secondary to pulmonary thromboembolism in a dog. J Vet Emerg Crit Care (San Antonio); 2009 Feb;19(1):120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumothorax secondary to pulmonary thromboembolism in a dog.
  • OBJECTIVE: To describe a case of spontaneous pneumothorax secondary to pulmonary thromboembolism possibly associated with pituitary dependent hyperadrenocorticism.
  • An exploratory thoracotomy was performed and revealed 2 lung lobes to be diffusely hemorrhagic and they were resected.
  • A 2-3 cm thrombus was visualized distal to the bifurcation of the pulmonary artery during an echocardiographic examination postoperatively.
  • Diagnosis of pituitary dependent hyperadrenocorticism was confirmed based on follow-up endocrine testing.
  • NEW OR UNIQUE INFORMATION PROVIDED: This is the first report of pulmonary thromboembolism causing spontaneous pneumothorax in the dog.
  • [MeSH-major] Dog Diseases / diagnosis. Pneumothorax / veterinary. Pulmonary Embolism / veterinary
  • [MeSH-minor] Adrenocortical Hyperfunction / diagnosis. Adrenocortical Hyperfunction / veterinary. Animals. Antineoplastic Agents, Hormonal / therapeutic use. Blood Coagulation. Dogs. Female. Mitotane / therapeutic use

  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691593.001).
  • [ISSN] 1476-4431
  • [Journal-full-title] Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
  • [ISO-abbreviation] J Vet Emerg Crit Care (San Antonio)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


52. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res; 2006 Mar 1;12(5):1533-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are biologically aggressive and have a tendency towards visceral metastasis when untreated.
  • Fascin expression has been associated with lung metastasis in breast cancer.
  • Tumors with a basal-like phenotype showed local recurrence (17.4%) or visceral metastasis (13%) but not bone metastasis (P = 0.001).
  • CONCLUSIONS: Basal-like tumors had a tendency towards visceral metastasis and their prognosis was dependent on the use of postoperative chemotherapy.
  • Although fascin expression was associated with the basal-like phenotype, it was not associated with their metastatic behavior.
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. BRCA1 Protein / metabolism. BRCA2 Protein / metabolism. Female. Humans. Keratin-5. Keratin-6. Keratins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Phenotype. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533778.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Microfilament Proteins; 0 / Receptors, Estrogen; 146808-54-0 / fascin; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


53. Yoneyama K, Yamada A, Koshida Y, Toriumi F, Murayama T, Toeda H, Imazu Y, Motegi K, Akamatsu H, Ooyama R: [A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1].
  • We report a 60-year-old female with pulmonary metastasis from breast cancer who responded to S-1.
  • After the fourth course, the tumor marker level returned to the reference value.
  • Thoracic CT at the end of the sixth course revealed the disappearance of the metastatic focus.
  • S-1 showed potent antitumor effects and good tolerance, and it may be useful for treating metastatic/recurrent breast cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Mastectomy, Segmental. Middle Aged. Mucin-1 / blood. Quality of Life

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637559.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 0 / Mucin-1; 0 / ST 439 antigen, human; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


54. Folberg R, Leach L, Valyi-Nagy K, Lin AY, Apushkin MA, Ai Z, Barak V, Majumdar D, Pe'er J, Maniotis AJ: Modeling the behavior of uveal melanoma in the liver. Invest Ophthalmol Vis Sci; 2007 Jul;48(7):2967-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 15-muL suspension of metastatic MUM2B or either primary OCM1 or M619 uveal melanoma cells was injected into the liver parenchyma of 105 CB17 SCID mice through a 1-cm abdominal incision.
  • RESULTS: OCM1a cells formed microscopic nodules in the mouse liver within 2 weeks after injection and metastasized to the lung 6 weeks later.
  • By contrast, M619 and MUM2B cells formed expansile nodules in the liver within 2 weeks and gave rise to pulmonary metastases within 4 weeks after injection.
  • Vasculogenic mimicry patterns, composed of human laminin and identical with those in human primary and metastatic uveal melanomas, were detected in the animal model.
  • The detection of human rather than mouse laminin in the vasculogenic mimicry patterns in this model demonstrates that these patterns were of tumor cell origin and were not co-opted from the mouse liver microenvironment.
  • CONCLUSIONS: There are currently no effective treatments for metastatic uveal melanoma.
  • This direct-injection model focuses on critical interactions between the tumor cell and the liver.
  • It provides for translationally relevant approaches to the development of new modalities to detect small tumor burdens in patients, to study the biology of clinical dormancy of metastatic disease in uveal melanoma, to design and test novel treatments to prevent the emergence of clinically manifest liver metastases after dormancy, and to treat established uveal melanoma metastases.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):383-8 [10666365.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1376-89 [17003493.001]
  • [Cites] Melanoma Res. 2000 Jun;10(3):195-211 [10890373.001]
  • [Cites] Arch Ophthalmol. 2001 Dec;119(12):1805-9 [11735791.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Apr;43(4):912-8 [11923228.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2533-9 [12147581.001]
  • [Cites] Lab Invest. 2002 Aug;82(8):1031-43 [12177242.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3045-52 [12202528.001]
  • [Cites] Microvasc Res. 2002 Sep;64(2):207-13 [12204644.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2834-40 [12824220.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9 [14578381.001]
  • [Cites] Am J Ophthalmol. 2004 Feb;137(2):236-43 [14962411.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2056-64 [15223777.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1980 Jul;19(7):760-70 [7390722.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1981 May;20(5):606-24 [6260703.001]
  • [Cites] Arch Ophthalmol. 1985 Jun;103(6):758 [2860887.001]
  • [Cites] Hum Pathol. 1985 Jul;16(7):689-92 [2408986.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1987 Aug;28(8):1397-403 [3497133.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1987 Nov;28(11):1844-50 [3117718.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):449-57 [2925275.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):164-8 [1846036.001]
  • [Cites] Matrix. 1991 Jun;11(3):151-60 [1714537.001]
  • [Cites] Ophthalmology. 1992 Jun;99(6):977-86 [1630787.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(6):433-7 [8333146.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3533-9 [8056529.001]
  • [Cites] Mol Carcinog. 1995 Feb;12(2):82-90 [7662120.001]
  • [Cites] Br J Ophthalmol. 1997 Mar;81(3):240-6; discussion 247-8 [9135390.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2738-46 [9326241.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):113-9 [17536318.001]
  • [Cites] Am J Ophthalmol. 1998 Aug;126(2):303-5 [9727526.001]
  • [Cites] Br J Ophthalmol. 1998 Aug;82(8):953-60 [9828784.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2800-5 [9856795.001]
  • [Cites] Curr Eye Res. 1999 Feb;18(2):125-9 [10223656.001]
  • [Cites] Eye (Lond). 1998;12 ( Pt 6):945-8 [10325992.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Am J Ophthalmol. 1961 May;51:977-93 [13689204.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):508-25 [15563313.001]
  • [Cites] Mol Vis. 2004 Dec 23;10:987-95 [15623988.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):453-60 [15672870.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1187-203 [15793298.001]
  • [Cites] Comput Med Imaging Graph. 2005 Jul;29(5):313-8 [15893451.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):422-8 [15886904.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jul;129(7):884-92 [15974811.001]
  • [Cites] Arch Ophthalmol. 2005 Aug;123(8):1088-94 [16087843.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jan;47(1):7-16 [16384938.001]
  • [Cites] J Microsc. 2006 Jan;221(Pt 1):30-45 [16438687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3752-7 [16505384.001]
  • [Cites] Curr Eye Res. 2006 Jun;31(6):557-62 [16769615.001]
  • [Cites] Melanoma Res. 2000 Feb;10(1):2-8 [10711634.001]
  • (PMID = 17591861.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY010457; United States / NEI NIH HHS / EY / EY 10797; United States / NEI NIH HHS / EY / R01 EY010457-13; United States / NEI NIH HHS / EY / EY010457-13; United States / NEI NIH HHS / EY / R01 EY10457
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Laminin
  • [Other-IDs] NLM/ NIHMS27644; NLM/ PMC1986739
  •  go-up   go-down


55. Khorgami Z, Nasiri S, Rezakhanlu F, Sodagari N: Malignant schwannoma of anterior abdominal wall: report of a case. J Clin Med Res; 2009 Oct;1(4):233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant schwannoma of anterior abdominal wall: report of a case.
  • Malignant schwannoma of the anterior abdominal wall nerves is extremely rare.
  • Malignant peripheral nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue sarcomas and it is found in 4% of patients with neurofibromatosis 1.
  • We present a case of malignant schwannoma in a 28-year-old female patient with neurofibromatosis 1.
  • She presented with a painful mass in the right upper quadrant of her abdomen.
  • The tumor location was in the abdominal wall in explorative laparatomy and malignant schwannoma was diagnosed in pathologic assessment.
  • The tumor recurred in 3 months and computed tomography showed two masses in the right side of abdominopelvic cavity.
  • In spite of administering chemotherapy after second surgery,the tumor recurred and magnetic resonance imaging finding showed a huge heterogeneously enhancing mass with adhesion to the inner side of the abdominal wall.
  • The patient died because of acute respiratory failure due to multiple bilateral pulmonary metastases.
  • Tumor location and rapid recurrence was unique in our patient.
  • KEYWORDS: Malignant peripheral nerve sheath tumor; Malignant schwannoma; Abdominal wall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22461875.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3299187
  •  go-up   go-down


56. Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF: Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol; 2010 Apr;62(4):470-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts.
  • OBJECTIVES: Osteosarcoma (OS) is the most common primary malignant bone tumour, and mainly affects adolescents and young adults.
  • The primary lesion in bone and ensuing metastasis in OS both require the induction of OCLs.
  • KEY FINDINGS: In an orthotopic model in Balb/c nu/nu mice, a twice weekly dosing regimen of 350 microg of RANK-Fc per mouse subcutaneously (n= 5) reduced lung metastasis (P > 0.05), preserved bone structure and reduced tartrate-resistant acid phosphatase (TRAP)(+) OCLs (P < 0.005) in OS-bearing bone.
  • [MeSH-minor] Acid Phosphatase / metabolism. Animals. Apoptosis / drug effects. Bone Resorption / drug therapy. Disease Models, Animal. Humans. Isoenzymes / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Male. Mice. Mice, Inbred BALB C. Mice, Knockout

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20604836.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RANK Ligand; 0 / Rank-Fc; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Recombinant Fusion Proteins; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


57. Lee H, Cho JY, Kim SH, Jung DC, Kim JK, Choi HJ: Imaging findings of primitive neuroectodermal tumors of the kidney. J Comput Assist Tomogr; 2009 Nov-Dec;33(6):882-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study was designed to present the radiological imaging findings of a renal primitive neuroectodermal tumor (PNET).
  • We assessed the size, margin, internal architecture, enhancement pattern, vein thrombosis, and presence of a metastasis of the tumors on multidetector-row computed tomography and magnetic resonance imaging.
  • The mean diameter of a renal PNET was 12.7 cm.
  • All masses were well defined with a lobulated contour.
  • A lymph node metastasis was detected in 3 patients.
  • A lung metastasis was detected in 4 patients, and 2 of the patients also had a bone metastasis.
  • CONCLUSIONS: A renal PNET usually appears as a weakly enhanced large mass with multiple septumlike structures, peripheral hemorrhage, venous thrombosis, and accompanied with a distant metastasis in a young adult.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940655.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


58. Pulukuri SM, Gorantla B, Knost JA, Rao JS: Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene; 2009 Aug 6;28(31):2829-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
  • Recent studies have shown that experimental manipulation of CST6 expression alters the metastatic behavior of human breast cancer cells.
  • However, the association of CST6 with prostate cancer invasion and progression remains unclear.
  • Here, we show that CST6 is robustly expressed in normal human prostate epithelium, whereas its expression is downregulated in metastatic prostate cell lines and prostate tumor tissues.
  • Treatment of metastatic prostate cell lines with the histone deacetylase inhibitor trichostatin A resulted in significant induction of CST6 mRNA levels and increased CST6 protein expression, indicating that epigenetic silencing may play a role in the loss of CST6 expression observed in prostate cancer.
  • CST6 overexpression in human prostate cancer cells significantly reduced in vitro cell proliferation and matrigel invasion.
  • Furthermore, the results from a bioluminescence tumor/metastasis model showed that the overexpression of CST6 significantly inhibits tumor growth and the incidence of lung metastasis.
  • These results suggest that the downregulation of the CST6 gene is associated with promoter histone modifications and that this association plays an important role in prostate cancer progression during the invasive and metastatic stages of the disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34940-7 [10574969.001]
  • [Cites] Lab Invest. 2008 Sep;88(9):910-25 [18607344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):759-60 [11309319.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20085-92 [11274215.001]
  • [Cites] Cancer Gene Ther. 2001 Jul;8(7):522-8 [11498774.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8705-12 [12483523.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):271-86 [12785001.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):761-9 [14970850.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2206-15 [14676833.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2224-30 [14730346.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6957-64 [15466187.001]
  • [Cites] FEBS Lett. 1991 Jul 22;285(2):213-9 [1855589.001]
  • [Cites] Cancer Treat Res. 1994;71:299-309 [7946954.001]
  • [Cites] Methods Enzymol. 1994;244:685-700 [7845245.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2170-80 [7857719.001]
  • [Cites] Enzyme Protein. 1996;49(1-3):94-105 [8797000.001]
  • [Cites] J Biol Chem. 1997 Jan 10;272(2):903-10 [8995380.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10853-8 [9099741.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] J Biol Chem. 1999 Jul 2;274(27):19195-203 [10383426.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2621-34 [17043644.001]
  • [Cites] Oncogene. 2007 May 10;26(21):3089-94 [17099723.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6637-46 [17638874.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5229-37 [17325663.001]
  • [Cites] J Biol Chem. 2007 Dec 7;282(49):35594-603 [17923479.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):740-54 [18506750.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):98-111 [10708852.001]
  • (PMID = 19503093.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092393-05; United States / NINDS NIH HHS / NS / R01 NS061835; United States / NCI NIH HHS / CA / R01 CA092393-05; United States / NCI NIH HHS / CA / R01 CA138409-01A1; United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557-11; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA116708-03; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NINDS NIH HHS / NS / R01 NS047699-05; United States / NCI NIH HHS / CA / R01 CA138409; United States / NCI NIH HHS / CA / CA138409-01A1; United States / NCI NIH HHS / CA / CA095058-05; United States / NINDS NIH HHS / NS / NS57529; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA138409; United States / NINDS NIH HHS / NS / R01 NS061835-01; United States / NCI NIH HHS / CA / R01 CA116708-04; United States / NINDS NIH HHS / NS / R01 NS057529-03; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / CA116708-03; United States / NINDS NIH HHS / NS / NS047699-05; United States / NCI NIH HHS / CA / CA075557-10; United States / NINDS NIH HHS / NS / NS061835-01; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NCI NIH HHS / CA / CA92393; United States / NCI NIH HHS / CA / CA095058-04; United States / NCI NIH HHS / CA / CA116708-04; United States / NINDS NIH HHS / NS / NS61835; United States / NINDS NIH HHS / NS / NS057529-03; United States / NCI NIH HHS / CA / R01 CA095058-05; United States / NCI NIH HHS / CA / R01 CA075557-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CST6 protein, human; 0 / Chromatin; 0 / Cystatin M; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Hydroxamic Acids; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS114954; NLM/ PMC2722685
  •  go-up   go-down


59. Słomiński JM, Kedziora K: [Is COPD an autoimmune disease caused by smoking?]. Przegl Lek; 2006;63(10):1138-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cigarette smoking is the main trigger for the development of chronic obstructive pulmonary disease (COPD).
  • This reaction will proceed over time to damage the lung, producing peptides and modified proteins from matrix destruction, cell necrosis and cell apoptosis.
  • Dendritic cells which are abundantly present in smokers' lungs are important link between innate and adaptive immunity involving T-cells.
  • So one of the possible conclusions could be that COPD is a disease produced, at least in part, by self-antigens from the lung secondary to smoking.
  • [MeSH-major] Autoimmune Diseases / epidemiology. Autoimmunity / immunology. Inflammation / epidemiology. Pulmonary Disease, Chronic Obstructive / epidemiology. Smoking / epidemiology. Smoking / immunology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17288238.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 9
  •  go-up   go-down


60. Tsutani Y, Ohsumi S, Aogi K, Taira N, Kataoka M, Hamamoto Y, Nishimura R, Takashima S: A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer; 2006;13(4):374-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.
  • An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast.
  • Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed.
  • CT revealed multiple lung metastases.
  • As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended.
  • Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla.
  • CT showed no lung tumors.
  • Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.
  • [MeSH-minor] Aged, 80 and over. Antibodies, Monoclonal, Humanized. Female. Humans. Lymphatic Metastasis. Trastuzumab


61. Ricciardelli L, Rapicano G, Pinto A, Napolitano G, Feleppa C, Martino G, Martino A: [Small bowel intussusception caused by metastasis from anaplastic thyroid carcinoma: case report and literature review]. Ann Ital Chir; 2006 Jan-Feb;77(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small bowel intussusception caused by metastasis from anaplastic thyroid carcinoma: case report and literature review].
  • [Transliterated title] Invaginazione ileo-ileale da metastasi di carcinoma anaplastico tiroideo. Caso clinico e revisione della letteratura.
  • Symptomatic involvement of the small bowel by metastasis from an extra-abdominal primary malignancy is rare, most commonly resulting from malignant melanoma and lung cancer; very rarely is small bowel involvement as first metastatic site.
  • The Authors report a case of anaplastic thyroid carcinoma with lung metastasis, brain metastasis and an isolated metastasis to the small bowel leading intestinal obstruction due to small bowel intussusception.
  • The Authors review the international literature about frequency, etiopathogenesis, clinical and diagnostic features and therapy of small bowel metastasis by extra-abdominal malignancies, especially by primary anaplastic thyroid carcinoma.
  • Small bowel metastasis from extra-abdominal malignancies are very unusual, especially from anaplastic thyroid carcinoma, and the etiopathogenesis is still unknown.
  • Computed Tomography has an important role in detecting the type of intestinal obstruction despite it is often unable to diagnose an isolated metastasis.
  • Best therapy is surgical resection, that allows the assessment of metastasis and the definitive staging.
  • The prognosis is poor, despite long-term survival has been occasionally reported for isolated small bowel metastasis
  • [MeSH-major] Carcinoma / complications. Carcinoma / diagnosis. Ileal Neoplasms / complications. Ileal Neoplasms / diagnosis. Intussusception / etiology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Brain Neoplasms / secondary. Female. Humans. Ileal Diseases / etiology. Lung Neoplasms / secondary. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910363.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 37
  •  go-up   go-down


62. Lim DH, Lee J, Lee HG, Park BB, Peck KR, Oh WS, Ji SH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Park K: Pulmonary complications after hematopoietic stem cell transplantation. J Korean Med Sci; 2006 Jun;21(3):406-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary complications after hematopoietic stem cell transplantation.
  • Despite advanced effective prophylaxes, pulmonary complications still occur in a high proportion of all hematopoietic stem cell recipients, accounting for considerable morbidity and mortality.
  • The aim of our study was to describe the causes, incidences and mortality rates secondary to pulmonary complications and risk factors of such complications following hematopoietic stem cell transplantation (HSCT).
  • The timing of pulmonary complications was divided into pre-engraftment, early and late period.
  • The spectrum of pulmonary complications included infectious and non-infectious conditions.
  • 73 of the 287 patients (25.4%) developed pulmonary complications.
  • The overall mortality rate from pulmonary complications was 28.8%.
  • Allogeneic transplant, grade II-IV acute graft-versus-host disease (GVHD) and extensive chronic GVHD were the risk factors with statistical significance for pulmonary complications after HSCT.
  • The mortality rates from pulmonary complications following HSCT were high, especially those of viral and fungal pneumonia, diffuse alveolar hemorrhage and idiopathic pneumonia syndrome.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lung Diseases / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Bacterial Infections / etiology. Female. Graft vs Host Disease. Humans. Lung / microbiology. Male. Middle Aged. Transplantation Conditioning. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1988 Nov 15;109(10):777-82 [2847609.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Nov 15;166(10):1364-8 [12406834.001]
  • [Cites] Chest. 1985 Feb;87(2):237-46 [2981658.001]
  • [Cites] Rev Infect Dis. 1982 Nov-Dec;4(6):1119-32 [6296961.001]
  • [Cites] Chest. 2004 Feb;125(2):712-22 [14769756.001]
  • [Cites] Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1601-6 [8503576.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):69-73 [7536723.001]
  • [Cites] Transplantation. 1995 Oct 15;60(7):672-8 [7570975.001]
  • [Cites] Chest. 1997 Jan;111(1):135-41 [8996007.001]
  • [Cites] Transplantation. 1997 Apr 27;63(8):1079-86 [9133468.001]
  • [Cites] Clin Infect Dis. 1997 Sep;25(3):551-73 [9314442.001]
  • [Cites] J Thorac Imaging. 1999 Jan;14(1):9-24 [9894950.001]
  • [Cites] Radiology. 1999 Mar;210(3):699-710 [10207470.001]
  • [Cites] Chest. 1999 Oct;116(4):1012-8 [10531167.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(4):223-9 [11349809.001]
  • [Cites] Bone Marrow Transplant. 2001 Sep;28(5):425-34 [11593314.001]
  • [Cites] Blood. 2003 Jan 15;101(2):407-14 [12393659.001]
  • [Cites] Clin Transplant. 2003 Aug;17(4):338-46 [12868990.001]
  • [Cites] Chest. 2003 Dec;124(6):2400-3 [14665531.001]
  • [Cites] J Thorac Imaging. 1987 Jul;2(3):68-79 [3612923.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Sep 1;166(5):641-5 [12204858.001]
  • [Cites] Semin Respir Infect. 2002 Jun;17(2):130-9 [12070832.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] Chest. 2002 Feb;121(2):527-32 [11834668.001]
  • [Cites] J Infect Dis. 2002 Feb 1;185(3):273-82 [11807708.001]
  • [Cites] Ann Intern Med. 1988 Nov 15;109(10):783-8 [2847610.001]
  • [Cites] Transplantation. 1988 Dec;46(6):905-7 [2849818.001]
  • [Cites] Am J Med. 1989 Nov;87(5):511-8 [2816966.001]
  • [Cites] J Pediatr Surg. 1990 Aug;25(8):871-6; discussion 876-7 [2401942.001]
  • [Cites] Am Rev Respir Dis. 1992 Aug;146(2):485-91 [1489145.001]
  • [Cites] Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1393-400 [8503550.001]
  • (PMID = 16778380.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2729942
  •  go-up   go-down


63. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA: Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell; 2007 Aug;12(2):160-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.
  • Transformation of these two cell populations with the same set of genetic elements yielded cells that formed tumor xenografts exhibiting major differences in histopathology, tumorigenicity, and metastatic behavior.
  • Transformed BPECs gave rise to lung metastases and were up to 10(4)-fold more tumorigenic than transformed HMECs, which are nonmetastatic.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adult. Animals. Antigens, Polyomavirus Transforming / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Cell Division. Cells, Cultured. Female. Gene Expression Profiling. Genes, ras / physiology. Humans. Mice. Mice, Inbred BALB C. Mice, Inbred NOD. Mice, Nude. Mice, SCID. Middle Aged. Transplantation, Heterologous


64. Mochizuki T, Okumura S, Ishii G, Ishikawa Y, Hayashi R, Kawabata K, Yoshida J: Surgical resection for oral tongue cancer pulmonary metastases. Interact Cardiovasc Thorac Surg; 2010 Jul;11(1):56-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection for oral tongue cancer pulmonary metastases.
  • The aim of this study was to evaluate the efficacy of surgical resection of oral tongue cancer (OTC) pulmonary metastases.
  • Between 1977 and 2003, 23 OTC patients who developed 1-3 pulmonary metastases underwent metastasectomy.
  • There were 14 men and nine women with a median age at the time of first metastasectomy of 56 years.
  • All patients had advanced squamous cell OTC with synchronous or metachronous regional lymph node metastases.
  • The median tumor-free interval after the last OTC treatment was 12 months.
  • Two patients underwent a second pulmonary metastasectomy.
  • Twenty-two out of 23 patients developed systemic metastases.
  • The median interval to systemic recurrence after lung resection was 4.1 months, and 21 out of 23 patients died of OTC (median, 9.5 months) after metastasectomy.
  • Most patients who underwent pulmonary metastasectomy died of the disease within two years of metastasectomy.
  • Even for patients with a solitary metastasis, surgical metastasectomy is not a recommended treatment option.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Tongue cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357009.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Zhang Y, Li A, Wang Z, Han Z, He J, Ma J: Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model. J Drug Target; 2008 Nov;16(9):679-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model.
  • To determine whether pegylated liposomal doxorubicin (PLD) could control the metastasis beyond primary tumor, the efficacy of PLD was evaluated in terms of metastatic growth inhibition and increasing life span in a murine lung metastasis model.
  • As early as 20 days after C57BL/6 mice were inoculated with 2 x 10(6) murine Lewis lung carcinoma cells into the right legs, metastases could be observed in the lungs.
  • Comparing the metastatic status of the PLD treatment conducted one day with one week after the tumor implantation, pathological study of the metastasis in the lungs indicated that without the removal of primary tumor, PLD could prevent metastasis by suppressing the growth of primary tumor.
  • To evaluate the direct antimetastasis ability of PLD with clinical relevance, a surgery was performed to resect the tumor-bearing limb.
  • In this therapeutic model, PLD targeted directly to the metastasis in the lungs, which resulted in substantially longer survival time than free doxorubicin.
  • Despite the superiority of PLD over free doxorubicin in treating pulmonary metastasis, our observation suggested that without the removal of primary tumor, the effect of PLD was only modest, and surgery plus multiple injections of PLD will be the best choice for patients with metastatic disease.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / therapeutic use. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Animals. Drug Delivery Systems. Female. Lung / pathology. Mice. Mice, Inbred C57BL

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982516.001).
  • [ISSN] 1029-2330
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


66. Choi IK, Lee YS, Yoo JY, Yoon AR, Kim H, Kim DS, Seidler DG, Kim JH, Yun CO: Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther; 2010 Feb;17(2):190-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pressing challenge for contemporary gene therapy is to deliver enough therapeutic genes to enough cancer cells in vivo.
  • With the aim of improving viral distribution and tumor penetration, we explored the use of decorin to enhance viral spreading and tumor tissue penetration.
  • In both tumor spheroids and established solid tumors in vivo, tissue penetration potency of dl-LacZ-DCNG was greatly enhanced than those of dl-LacZ, dl-LacZ-DCNQ and dl-LacZ-DCNK, and this enhanced tissue penetration effect derived from decorin-expressing Ad was dependent on the binding affinity of decorin to collagen fibril.
  • Expression of DCNG enhanced viral spread of replicating Ad, leading to improved tumor reduction and survival benefit.
  • Moreover, the tumoricidal effects of Ad-DeltaE1B-DCNQ and Ad-DeltaE1B-DCNK were lessened, as the binding affinity to collagen was decreased, showing that the increased cancer cell cytotoxicity was driven by the action of decorin on extracellular matrix (ECM).
  • Furthermore, Ad-DeltaE1B-DCNG substantially decreased ECM components within the tumor tissue.
  • Finally, intratumoral injection of Ad-DeltaE1B-DCNG in primary tumor site greatly reduced the formation of B16BL6 melanoma cell pulmonary metastases in mice.
  • Taken together, these data show the utility of decorin as a dispersion agent and highlight its utility and potential in improving the efficacy of replicating Ad-mediated cancer gene therapy.
  • [MeSH-minor] Animals. Cell Line, Tumor. Decorin. Gene Transfer Techniques. Genetic Therapy. Mice. Mice, Nude. Spheroids, Cellular / metabolism. Transduction, Genetic. Xenograft Model Antitumor Assays

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907500.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dcn protein, mouse; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans
  •  go-up   go-down


67. Castañer E, Gallardo X, Rimola J, Pallardó Y, Mata JM, Perendreu J, Martin C, Gil D: Congenital and acquired pulmonary artery anomalies in the adult: radiologic overview. Radiographics; 2006 Mar-Apr;26(2):349-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital and acquired pulmonary artery anomalies in the adult: radiologic overview.
  • Various congenital and acquired anomalies may affect the pulmonary arteries in adult patients.
  • Congenital anomalies (proximal interruption, anomalous origin of the left pulmonary artery [pulmonary artery sling], and idiopathic dilatation of the pulmonary trunk) are usually found incidentally at chest radiography or computed tomography (CT).
  • Acquired anomalies include diffuse or focal enlargement of the arteries because of pulmonary hypertension, aneurysm, and intravascular pulmonary metastasis; decreased arterial diameter because of bronchial carcinoma, mediastinal fibrosis, and Takayasu arteritis; and intraluminal filling defects due to pulmonary thromboembolism and pulmonary artery sarcoma.
  • An awareness of the radiologic manifestations of the disease entities and potential pulmonary artery complications secondary to infection or vasculitis may enable an early diagnosis.
  • CT angiography is becoming the standard method for evaluating patients in whom the presence of pulmonary embolism is suspected.
  • CT assessment of the extent of heart effects in patients with pulmonary hypertension and pulmonary embolism is particularly important because such effects largely determine the prognosis.
  • [MeSH-major] Image Enhancement / methods. Pulmonary Artery / abnormalities. Pulmonary Artery / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 16549603.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


68. Tanaka A, Honma K, Kondo H: [A case of cerebellum metastasis from colon cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2242-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cerebellum metastasis from colon cancer].
  • We report a case of cerebellum metastasis from transverse colon cancer, which had no evidence of recurrence in the thoracoabdominal region by chemotherapy and resection of liver and lung metastases after initial operation.
  • We performed a radical resection of transverse colon cancer (D2) in 2001.
  • Relapsing tumor, which metastasized to the liver in 3 years, the right lung in 4 years and 8 months and the left lung in 5 years and 11 months after initial operation, were totally resected.
  • Following the partial resection of the left lung, he received a treatment with 12 times of mFOLFOX6 and S-1+PSK.
  • There was a good control observed in the thoracoabdominal region with no metastases for 14 months.
  • However, drift and dizziness developed in April 2008, and cerebellum metastasis was diagnosed by MRI.
  • He underwent a partial resection of cerebellum tumor, radiation therapy and FOLFIRI.
  • He has been alive for 1 year after the treatment of the cerebellum metastasis, and there has been no evidence of recurrence in the thoracoabdominal region in 8 years after initial operation.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Colonic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037383.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Tsutsui H, Usuda J, Kubota M, Yamada M, Suzuki A, Shibuya H, Miyajima K, Tanaka K, Sugino K, Ito K, Kato H: Endoscopic tumor ablation for laryngotracheal intraluminal invasion secondary to advanced thyroid cancer. Acta Otolaryngol; 2008 Jul;128(7):799-807
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic tumor ablation for laryngotracheal intraluminal invasion secondary to advanced thyroid cancer.
  • CONCLUSIONS: Endoscopic tumor ablation is a valuable option for inoperable postoperative laryngotracheal intraluminal invasion of well-differentiated thyroid carcinoma (DTC).
  • OBJECTIVES: To investigate whether DTC invasion to the laryngotracheal mucosa can be controlled by 'simple' tumor ablation considering its relatively slow-growing nature.
  • PATIENTS AND METHODS: Twenty-two consecutive patients underwent endoscopic tumor ablation caused by DTC for local control of intraluminal lesions with no significant extrinsic laryngotracheal compression in symptomatic or asymptomatic patients in whom radical operations were contraindicated.
  • Debulking by Nd:YAG laser was followed by electrocoagulation and microwave coagulation for the residual tumor base.
  • During the follow-up period of up to 125 months, 6 of 22 patients died (median survival 50 months), mainly of lung metastases, but all had a patent airway at death.
  • Lesions requiring retreatment within 1 year after initial treatment usually have high-grade malignancy, causing extrinsic compression, and prognosis is unfavorable.
  • [MeSH-minor] Aged. Aged, 80 and over. Bronchoscopy. Female. Follow-Up Studies. Humans. Lasers, Solid-State / therapeutic use. Male. Microwaves / therapeutic use. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568524.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


70. Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, Takase S, Kuroda D, Kim Y, Ajiki T, Kuroda Y: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother; 2007 Jul;56(7):1025-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
  • Cancer immunotherapy by dendritic cell (DC)/tumor cell fusion hybrids (DC/TC hybrids) has been shown to elicit potent anti-tumor effects via the induction of immune responses against multiple tumor-associated antigens.
  • In the present study, we compared the anti-tumor effects of vaccinating Balb/c mice (H-2(d)) with CT26CL25 colon carcinoma cells that had been fused with either syngeneic DCs from Balb/c mice, allogeneic DCs from C57BL/6 mice (H-2(b)) or semiallogeneic DCs from B6D2F1 mice (H-2(b/d)).
  • Preimmunization with either semiallogeneic or allogeneic DC/TC hybrids induced complete protection from tumor challenge, whereas mice preimmunized with syngeneic DC/TC hybrids were only partially protected (75% tumor rejection).
  • The average number of pulmonary metastases after intravenous tumor injection decreased significantly following immunization with semiallogeneic or allogeneic DC/TC hybrids (8.3 +/- 7.9 or 16.3 +/- 3.5, mean +/- SD) relative to syngeneic DC/TC hybrids (67.8 +/- 6.3).
  • These data demonstrate that vaccination with semiallogeneic DC/TC hybrids resulted in the greatest anti-tumor efficacy.
  • Anti-tumor effects showed by in vivo studies were virtually accomplished by the frequency of induced CTLs specific to both gp70 and beta-galactosidase assessed by using pentameric assay.
  • These findings suggest that in clinical settings, DCs derived from a healthy donor (which are generally characterized as more semiallogeneic than allogeneic) may be more capable than autologous DCs of inducing promising anti-tumor effects in vaccinations with DC/TC hybrids.
  • [MeSH-major] Adenocarcinoma / therapy. Cancer Vaccines / therapeutic use. Colonic Neoplasms / therapy. Dendritic Cells / immunology. Immunotherapy / methods
  • [MeSH-minor] Animals. Antigens, Neoplasm / immunology. Cell Fusion. Cytokines / immunology. Cytokines / metabolism. Flow Cytometry. Hybrid Cells. Mice. T-Lymphocytes, Cytotoxic / immunology. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131118.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Cytokines
  •  go-up   go-down


71. Santel A, Aleku M, Röder N, Möpert K, Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, Eisermann M, Löffler K, Fechtner M, Fisch G, Vank C, Schaeper U, Giese K, Kaufmann J: Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res; 2010 Nov 15;16(22):5469-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models.
  • PURPOSE: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models.
  • The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hematogenous metastasis to the target organ lung in four different preclinical mouse models.
  • EXPERIMENTAL DESIGN: Atu027 compared with vehicle or control small interfering RNA lipoplexes was tested in two experimental lung metastasis models (Lewis lung carcinoma, B16V) and spontaneous metastasis mouse models (MDA-MB-435, MDA-MB-231, mammary fat pad).
  • Primary tumor growth and lung metastasis were measured, and tissues were analyzed by immunohistochemistry and histology.
  • RESULTS: Intravenous administration of Atu027 prevents pulmonary metastasis.
  • In particular, formation of spontaneous lung metastasis was significantly inhibited in animals with large tumor grafts as well as in mice with resected primary mammary fat pad tumors.
  • CONCLUSION: Atu027 can be considered as a potent drug for preventing lung metastasis formation, which might be suitable for preventing hematogenous metastasis in addition to standard cancer therapy.
  • [MeSH-major] Carcinoma, Lewis Lung / prevention & control. Carcinoma, Lewis Lung / secondary. Disease Models, Animal. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. RNA Interference. RNA, Small Interfering / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 21062934.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Atu027; 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


72. Pan YW, Huang XY, You JF, Tian GL, Li C: [Malignant giant cell tumor of the tendon sheaths in the hand]. Zhonghua Wai Ke Za Zhi; 2008 Nov 1;46(21):1645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant giant cell tumor of the tendon sheaths in the hand].
  • OBJECTIVES: To retrospectively study on malignant giant cell tumor of tendon sheath (MGCTTS) in the hand, and to evaluate its clinical, histologic, immunohistochemical features and biologic evolution.
  • RESULTS: Three of 10 patients in which the diagnosis of MGCTTS was originally considered were excluded after the slides reviewed and immunohistochemical examination performed.
  • In the other 7 patients, one showed malignant and aggressive nature: the lesion recurred several times and the patient eventually died with pulmonary metastases.
  • Six cases presented histologic features of malignancy, 4 of them undertook the immunohistochemical examination and their profiles were similar to that reported in benign GCTTS.
  • CONCLUSIONS: Malignant giant cell tumor of tendon sheath is an extremely rare malignant tumor, some cases have a poor outcome, the others, despite the histologically malignant features, have a good prognosis if wide surgical excision ablates the tumor completely.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094761.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


73. Van Putte BP, Hendriks JM, Romijn S, De Greef K, Van Schil PE: Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases. Thorac Cardiovasc Surg; 2006 Mar;54(2):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
  • BACKGROUND: Long-term toxicity and efficacy of isolated left lung perfusion (ILuP) with gemcitabine (GCB) were studied in a rat model of metastatic pulmonary adenocarcinoma.
  • Efficacy experiment: Rats with unilateral metastases had ILuP with 320 mg/kg GCB (maximally tolerated dose administered by ILuP), while rats with bilateral metastases had an i.v. injection of 160 mg/kg GCB (maximally tolerated dose given by i.v.).
  • CONCLUSIONS: ILuP with GCB prolongs survival in experimental metastatic adenocarcinoma while no major acute or long term toxicity is observed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Colorectal Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Lung / drug effects. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541356.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


74. Virgo KS, Naunheim KS, Johnson FE: Preoperative workup and postoperative surveillance for patients undergoing pulmonary metastasectomy. Thorac Surg Clin; 2006 May;16(2):125-31, v
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative workup and postoperative surveillance for patients undergoing pulmonary metastasectomy.
  • The workup of patients suspected of having pulmonary metastases is complicated by the fact that a high percentage of pulmonary metastases are 6mm or less at presentation.
  • The follow-up of patients after pulmonary metastasectomy is a controversial topic because of the lack of evidence-based practice guidelines.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805201.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


75. Mesfin FB, Deshaies EM, Patel R, Weaver S, Spurgas P, Popp AJ: Metastatic gliosarcoma with a unique presentation and progression: case report and review of the literature. Clin Neuropathol; 2010 May-Jun;29(3):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gliosarcoma with a unique presentation and progression: case report and review of the literature.
  • Three years later, she developed an intensely enhancing centrally necrotic tumor in the right temporal-parietal lobes.
  • A craniotomy was performed with gross total resection of the tumor followed by chemotherapy and radiation treatments.
  • A year later, she had a recurrence of the intra-axial gliosarcoma requiring a second craniotomy for tumor resection and placement of Gliadel wafers.
  • A pulmonary workup revealed lung lesions that were biopsied and found to be gliosarcoma.
  • After the second surgery, she underwent pleurodesis and one cycle of modified mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy, but died 5 months later from progression of the lung metastases.
  • There are fewer than 20 reported cases of extracranial metastases of gliosarcoma.
  • This is the first report of gliosarcoma with prolonged survival (over 2 years) and death from non-CNS metastatic gliosarcoma.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / secondary. Gliosarcoma / secondary

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423688.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


76. Shi W, Tang Q, Chen X, Cheng P, Jiang P, Jing X, Chen X, Chen P, Wang Y, Wei Y, Wen Y: Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med (Berl); 2009 May;87(5):493-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer.
  • Vesicular stomatitis virus (VSV) matrix protein (MP) is capable of inducing in vitro apoptosis of tumor cells in the absence of other viral components.
  • Here, we report the potent antitumor and antimetastatic effects of recombinant plasmid pVAX-MP complexed with cationic liposome (DOTAP:Chol) against highly metastatic 4T1 mammary tumor.
  • Mice with 10-day established 4T1 metastatic carcinomas showed a significant reduction in spontaneous lung metastases as well as an evident inhibition in the growths of primary tumors yet without conspicuous systemic toxic effects following a 35-day course of intravenous therapy with pVAX-MP:liposome complexes once every 5 days; the therapy significantly prolonged the survival of the tumor-bearing mice consequently.
  • In summary, these results indicate that pVAX-MP:liposome complexes have the ability to inhibit the growths and metastases of mouse breast cancer and they may be a novel and potentially effective therapy against human advanced breast cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lung Neoplasms / prevention & control. Mammary Neoplasms, Experimental / drug therapy. Viral Matrix Proteins / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blood Vessels / drug effects. Blood Vessels / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Gene Expression. Immunohistochemistry. In Situ Nick-End Labeling. Kaplan-Meier Estimate. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Inbred BALB C. Plasmids / chemistry. Plasmids / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2004 Mar;9(3):368-76 [15006603.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] J Virol. 1992 Jul;66(7):4058-64 [1318397.001]
  • [Cites] Virology. 2004 Dec 5;330(1):34-49 [15527832.001]
  • [Cites] IUBMB Life. 2000 Aug;50(2):135-8 [11185959.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1243-52 [11106761.001]
  • [Cites] Vet Pathol. 2003 Sep;40(5):512-20 [12949408.001]
  • [Cites] J Virol. 2001 May;75(9):4453-8 [11287600.001]
  • [Cites] J Virol. 2007 Mar;81(6):2792-804 [17192316.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1515-25 [15173875.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1401-13 [9525983.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Neuropathol Appl Neurobiol. 1987 Mar-Apr;13(2):111-22 [3039392.001]
  • [Cites] J Virol. 2003 Apr;77(8):4646-57 [12663771.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):51-65 [14749126.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3162-70 [12626574.001]
  • [Cites] J Virol. 1995 Jun;69(6):3529-37 [7745700.001]
  • [Cites] Brain Res. 1994 Jan 28;635(1-2):81-95 [8173982.001]
  • [Cites] Mol Ther. 2002 Oct;6(4):519-27 [12377194.001]
  • [Cites] J Virol. 1993 Aug;67(8):4814-21 [8392615.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2710-5 [10825145.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1815-23 [12750177.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):263-75 [14585354.001]
  • [Cites] J Virol. 1991 Sep;65(9):4950-8 [1651414.001]
  • [Cites] Cancer Res. 1978 Oct;38(10):3174-81 [210930.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1584-91 [18436522.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Vet J. 1999 May;157(3):239-60 [10328837.001]
  • [Cites] Nat Biotechnol. 1997 Jul;15(7):647-52 [9219267.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1399-405 [1540948.001]
  • [Cites] J Virol. 1993 Nov;67(11):6698-706 [8105106.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):974-84 [9753714.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8590-601 [11046154.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1486-93 [9537252.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] J Virol. 1998 Oct;72(10):8413-9 [9733895.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5684-9 [7499854.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):409-18 [12668137.001]
  • [Cites] Nat Med. 2000 Jul;6(7):821-5 [10888934.001]
  • [Cites] J Virol. 1997 Jan;71(1):371-7 [8985359.001]
  • [Cites] Virology. 1998 Nov 25;251(2):383-92 [9837802.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):143-9 [15305386.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Science. 1997 Jun 20;276(5320):1845-8 [9188527.001]
  • [Cites] Virology. 1995 May 10;209(1):257-62 [7747478.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):7-11 [12892708.001]
  • (PMID = 19259640.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / M protein, Vesicular stomatitis virus; 0 / Viral Matrix Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


77. Caserta S, Alessi P, Guarnerio J, Basso V, Mondino A: Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses. Cancer Res; 2008 Apr 15;68(8):3010-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To overcome these limitations, we developed CD4(+) T cell-targeted synthetic microbead-based artificial APC (aAPC) and used them to activate CD4(+) T lymphocytes specific for a tumor-associated model antigen (Ag) directly from the naive repertoire.
  • In vitro, aAPC specifically primed Ag-specific CD4(+) T cells that were activated to express high levels of CD44, produced mainly interleukin 2, and could differentiate into Th1-like or Th2-like cells in combination with polarizing cytokines. I.v. administration of aAPC led to Ag-specific CD4(+) T-cell activation and proliferation in secondary lymphoid organs, conferred partial protection against subcutaneous tumors, and prevented the establishment of lung metastasis.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, Protozoan / immunology. Cancer Vaccines / therapeutic use. Drosophila melanogaster / immunology. Histocompatibility Antigens Class II / chemistry. Histocompatibility Antigens Class II / immunology. Mice. Mice, Inbred BALB C. Protozoan Proteins / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413771.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Protozoan; 0 / Cancer Vaccines; 0 / Histocompatibility Antigens Class II; 0 / Protozoan Proteins; 163832-69-7 / LACK antigen, Leishmania
  •  go-up   go-down


78. Middleton JR, Chigerwe M, Fine DM, Turk JR, Lattimer JC: Pulmonary hypertension and right-sided heart failure in an adult llama with hepatic disease. J Am Vet Med Assoc; 2006 Mar 1;228(5):756-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary hypertension and right-sided heart failure in an adult llama with hepatic disease.
  • CLINICAL FINDINGS: Physical examination revealed muffled heart and lung sounds and peripheral edema.
  • Echocardiography revealed severe dilatation of the right atrium, right ventricle, and pulmonary artery; severe tricuspid regurgitation; and high right ventricular systolic pressure consistent with right-sided heart failure secondary to pulmonary hypertension.
  • Macronodular cirrhosis of the liver, glomerulonephritis, and intimal fibrosis and medial hypertrophy of muscular pulmonary arteries were seen on histologic examination of postmortem specimens.
  • CLINICAL RELEVANCE: Findings in this case were similar to those reported for human patients with portopulmonary hypertension secondary to hepatic cirrhosis.
  • Pulmonary hypertension secondary to hepatic disease should be considered in the differential diagnosis of right-sided heart failure.
  • [MeSH-major] Camelids, New World. Heart Failure / veterinary. Hypertension, Pulmonary / veterinary. Liver Diseases / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Electrocardiography / veterinary. Fatal Outcome. Female

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506943.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES: Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res; 2010 Aug 1;16(15):4024-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
  • PURPOSE: Osteosarcoma most commonly recurs in the lung.
  • Based on preliminary data on the antitumor effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in animal models, and promising phase I trials, we embarked on a feasibility study of inhaled GM-CSF in patients with first isolated pulmonary recurrence of osteosarcoma.
  • Following two cycles, patients underwent thoracotomy to resect tumor and analyze pulmonary nodules for expression of Fas/Fas ligand (Fas/FasL), and the presence of dendritic cells by immunostaining for CD1a, clusterin, and S100.
  • However, no detectable immunostimulatory effect in pulmonary metastases or improved outcome postrelapse was seen.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Blood. 2001 Jan 15;97(2):339-45 [11154206.001]
  • [Cites] J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):197-206 [19803732.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):710-5 [12586810.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2050-7 [12957460.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):493-8 [14528078.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2447-56 [14635080.001]
  • [Cites] Eur J Cardiothorac Surg. 1990;4(9):477-81 [2223127.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1849-58 [8083708.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2614-20 [7989936.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1084-93 [7850705.001]
  • [Cites] Exp Hematol. 1995 May;23(5):402-6 [7536681.001]
  • [Cites] Bone Marrow Transplant. 1996 Jul;18(1):47-52 [8831995.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1202-8 [9301443.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3245-87 [9345009.001]
  • [Cites] Blood. 1998 Jan 1;91(1):222-30 [9414288.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4491-508 [9845514.001]
  • [Cites] J Leukoc Biol. 1999 Jan;65(1):102-8 [9886252.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2316-23 [10499599.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):559-68 [15659502.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):458-63 [15800950.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2214-21 [16206297.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):611-5 [16282894.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Jan;29(1):48-52 [17230066.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4503-10 [17671136.001]
  • [Cites] Am J Clin Oncol. 2008 Dec;31(6):573-9 [19060590.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):823-7 [12066216.001]
  • (PMID = 20576718.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS215757; NLM/ PMC2989183
  •  go-up   go-down


80. Siva S, MacManus M, Ball D: Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol; 2010 Jul;5(7):1091-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for pulmonary oligometastases: a systematic review.
  • INTRODUCTION: Hypofractionated stereotactic body radiotherapy (SBRT) is an emerging noninvasive technique for the treatment of oligometastatic cancer.
  • The aim of this literature review is to critically assess the use of SBRT for the treatment of pulmonary metastases as judged by its effect on local control, survival, and toxicity.
  • The corresponding 2-year weighted overall survival was 53.7%, with a 4% rate of grade 3 or higher radiation toxicities.
  • CONCLUSION: There was insufficient evidence to recommend a consensus view for optimal tumor parameters, dose fractionation, and technical delivery of treatment.
  • However, high local control rates that could potentially lead to a survival benefit justifies the consideration of stereotactic radiotherapy for patients with limited pulmonary oligometastases.
  • [MeSH-major] Lung Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Jul;5(7):927-9 [20581573.001]
  • (PMID = 20479693.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


81. Fiorentino F, Hunt I, Teoh K, Treasure T, Utley M: Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med; 2010 Feb;103(2):60-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis.
  • OBJECTIVES: Surgical removal of pulmonary metastases from colorectal cancer is undertaken increasingly but the practice is variable.
  • DESIGN: A formal search for all studies concerning the practice of pulmonary metastasectomy was undertaken including all published articles using pre-specified keywords.
  • Information across studies was collated in a quantitative synthesis.
  • There was little change over time in patient characteristics such as age, sex, the time elapsed since resection of the primary cancer, its site or stage.
  • The proportion with multiple metastases or elevated carcinoma embryonic antigen (CEA) did not change over time but there was an apparent increase in the proportion of patients who also had hepatic metastasectomy.
  • Differences in 5-year survival between groups defined by CEA or by single versus multiple metastases persisted over time.
  • Few data were available concerning postoperative morbidity, postoperative lung function or change in symptoms.
  • CONCLUSION: The quality of evidence available concerning pulmonary metastasectomy in colorectal cancer is not sufficient to draw inferences concerning the effectiveness of this surgery.
  • Given the burdensome nature of the surgery involved, better evidence, ideally in the form of a randomized trial, is required for the continuance of this practice.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy / statistics & numerical data

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Oncol. 2008 Nov;3(11):1257-66 [18978560.001]
  • [Cites] Eur J Surg Oncol. 2009 Jul;35(7):686-9 [19153025.001]
  • [Cites] World J Surg. 2009 Mar;33(3):505-11 [19148702.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 Mar;35(3):444-9 [19136273.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):732-9 [14502146.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1436-40 [14598428.001]
  • [Cites] Am Surg. 2003 Dec;69(12):1047-53; discussion 1053 [14700289.001]
  • [Cites] Br J Surg. 2004 Jan;91(1):112-20 [14716804.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Feb;25(2):151-4 [14747104.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):238-44 [15223436.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):1066-71 [15286972.001]
  • [Cites] Clin Colorectal Cancer. 2004 Jul;4(2):101-6 [15285817.001]
  • [Cites] J Thorac Cardiovasc Surg. 1971 Jan;61(1):23-32 [4322187.001]
  • [Cites] Ann Thorac Surg. 1980 Oct;30(4):378-84 [7425716.001]
  • [Cites] Dis Colon Rectum. 1985 Aug;28(8):562-4 [4017819.001]
  • [Cites] Chest. 1986 Jan;89(1):109-12 [3940769.001]
  • [Cites] Dis Colon Rectum. 1988 Oct;31(10):786-92 [3168665.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1418-21 [2776104.001]
  • [Cites] Dis Colon Rectum. 1990 Sep;33(9):745-52 [2390909.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1387-92; discussion 1392-3 [2222179.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 May;101(5):901-8 [2023448.001]
  • [Cites] Arch Surg. 1991 Oct;126(10):1297-301; discussion 1302 [1929833.001]
  • [Cites] Ann Thorac Surg. 1992 May;53(5):780-5; discussion 785-6 [1570970.001]
  • [Cites] Dis Colon Rectum. 1993 May;36(5):425-9 [8482160.001]
  • [Cites] Rev Mal Respir. 1999 Nov;16(5):809-15 [10612150.001]
  • [Cites] ANZ J Surg. 2001 Mar;71(3):143-6 [11277142.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Apr;121(4):657-67 [11279405.001]
  • [Cites] Chest. 2001 Apr;119(4):1069-72 [11296171.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Jun;19(6):908-13 [11404151.001]
  • [Cites] Can J Surg. 2001 Jun;44(3):217-21 [11407833.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2002 Jan;65(1):15-22 [11939670.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):906-12 [12062285.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1164-8 [12190683.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Nov;124(5):1007-13 [12407386.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):629-36 [12792439.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jul;51(7):289-96 [12892459.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):386-91 [12946793.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Nov;106(5):875-9 [8231210.001]
  • [Cites] Respiration. 1994;61(5):280-2 [7800960.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1403-6 [1365684.001]
  • [Cites] Chest. 1995 Jun;107(6):1526-31 [7781341.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):353-61 [8605559.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):393-8 [8625119.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2047-53 [8683235.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Oct;112(4):867-74 [8873711.001]
  • [Cites] Tohoku J Exp Med. 1996 Oct;180(2):153-60 [9111764.001]
  • [Cites] Eur J Surg Oncol. 1997 Oct;23(5):424-7 [9393571.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1998 Aug;8(4):195-200 [9755910.001]
  • [Cites] J Cardiovasc Surg (Torino). 1998 Aug;39(4):503-7 [9788801.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):278-82; discussion 283 [15620957.001]
  • [Cites] World J Surg. 2005 Mar;29(3):363-8 [15706447.001]
  • [Cites] Clin Trials. 2005;2(3):218-29; discussion 229-32 [16279145.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):982-99 [16538219.001]
  • [Cites] Ann Thorac Surg. 2006 Jul;82(1):254-60 [16798225.001]
  • [Cites] Jpn J Clin Oncol. 2006 Oct;36(10):643-8 [16931541.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1538-44 [17009154.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Feb;31(2):167-72 [17150367.001]
  • [Cites] BMJ. 2007 Feb 17;334(7589):349-51 [17303884.001]
  • [Cites] BMJ. 2007 Apr 21;334(7598):831-2 [17446615.001]
  • [Cites] Ann Thorac Surg. 2007 Jul;84(1):324-38 [17588454.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 May;35(5):792-6 [19233682.001]
  • [Cites] Surg Endosc. 2009 Jan;23(1):55-61 [18437482.001]
  • (PMID = 20118336.001).
  • [ISSN] 1758-1095
  • [Journal-full-title] Journal of the Royal Society of Medicine
  • [ISO-abbreviation] J R Soc Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  • [Other-IDs] NLM/ PMC2813785
  •  go-up   go-down


82. Meijer J, Ogink J, Roos E: Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer; 2008 Nov 4;99(9):1493-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results differ from those in a previous report on other carcinoma cells.
  • Nevertheless, we observed no effect of complete and stable CXCR7 suppression on the growth of s.c. tumours or lung metastases of KEP1 and CT26 cells.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Chemokine CXCL12 / physiology. Chemotaxis. Humans. Mice. Mice, Nude. RNA Interference

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4701-8 [18559516.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):269-77 [11457880.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 23;11(14):1897-902 [11459656.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1969-74 [12702590.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3833-9 [12839981.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):307-11 [13679920.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1391-402 [14597738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):171-8 [15081542.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1110-6 [9334722.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):6996-7007 [9384579.001]
  • [Cites] Nat Med. 1998 Jan;4(1):72-7 [9427609.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1743-50 [15755995.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1835-41 [15756007.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2744-53 [15837989.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35760-6 [16107333.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1237-50 [16230077.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1281-8 [16200065.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1840-7 [16368946.001]
  • [Cites] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9576-82 [17018614.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):651-8 [17234775.001]
  • [Cites] Mol Cancer Res. 2007 Jan;5(1):21-33 [17259344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40 [17898181.001]
  • [RetractionIn] Roos E. Br J Cancer. 2011 Jan 4;104(1):227 [21206499.001]
  • (PMID = 18854833.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR7 protein, human; 0 / Chemokine CXCL12; 0 / Cmkor1 protein, mouse; 0 / Receptors, CXCR
  • [Other-IDs] NLM/ PMC2579699
  •  go-up   go-down


83. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH: SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res; 2006 Jun 1;66(11):5599-607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition.
  • SSeCKS, a Src-suppressed protein kinase C substrate with metastasis suppressor activity, is the rodent orthologue of human gravin/AKAP12, a scaffolding protein for protein kinase A and protein kinase C.
  • We show here that the tetracycline-regulated reexpression of SSeCKS in MatLyLu (MLL) prostate cancer cells suppressed formation of macroscopic lung metastases in both spontaneous and experimental models of in vivo metastasis while having minimal inhibitory effects on the growth of primary-site s.c. tumors.
  • SSeCKS decreased angiogenesis in vitro and in vivo by suppressing vascular endothelial growth factor (VEGF) expression in MLL tumor cells as well as in stromal cells.
  • The forced reexpression of VEGF(165) and VEGF(121) isoforms was sufficient to reverse aspects of SSeCKS metastasis-suppressor activity in both the experimental and spontaneous models.
  • These results suggest that SSeCKS suppresses formation of metastatic lesions by inhibiting VEGF expression and by inducing soluble antiangiogenic factors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740695.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094108; United States / NCI NIH HHS / CA / CA94108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / A Kinase Anchor Proteins; 0 / AKAP12 protein, human; 0 / Akap12 protein, mouse; 0 / Akap12 protein, rat; 0 / Cell Cycle Proteins; 0 / Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


84. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ: In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem; 2005 Jun 16;48(12):4161-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro biological experiments demonstrate that these compounds are active toward the TS/A mouse adenocarcinoma cancer cell line whereas cytotoxicity on the HBL-100 human mammary (nontumor) cell line was not observed at concentrations up to 0.3 mM, which indicates selectivity of these ruthenium(II)-arene complexes to cancer cells.
  • The results show that these complexes can reduce the growth of lung metastases in CBA mice bearing the MCa mammary carcinoma in the absence of a corresponding action at the site of primary tumor growth.
  • [MeSH-minor] Animals. Buffers. Cell Line, Tumor. DNA / chemistry. Female. Humans. Hydrolysis. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mammary Neoplasms, Experimental / pathology. Mice. Mice, Inbred CBA. Sodium Chloride. Solutions. Structure-Activity Relationship. Tissue Distribution. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943488.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1,3,5-triaza-7-phosphaadamantane; 0 / Antineoplastic Agents; 0 / Benzene Derivatives; 0 / Buffers; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Solutions; 451W47IQ8X / Sodium Chloride; 7UI0TKC3U5 / Ruthenium; 9007-49-2 / DNA; 91080-16-9 / calf thymus DNA; PJY633525U / Adamantane
  •  go-up   go-down


85. Krishnan K, Khanna C, Helman LJ: The molecular biology of pulmonary metastasis. Thorac Surg Clin; 2006 May;16(2):115-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The molecular biology of pulmonary metastasis.
  • Curing cancer requires the treatment of metastatic disease.
  • Whether this is a patient with advanced disease and clinically apparent metastases, or if the patient with localized disease is at risk for development of dissemination, failure to control metastasis will result in a poor outcome.
  • Here, we have presented a molecular guide to our current understanding of the processes underlying metastasis.
  • Experimental clinical trials designed to further the understanding of metastasis are often limited by selection of patients with advanced disease.
  • Therefore, our understanding of the processes involved in the metastatic cascade is limited by the availability of comprehensive experimental model systems.
  • The study of metastasis relies most heavily on xenografts, tumors using human cell lines, or tumor tissue that can grow in mice.
  • As the evasion of the immune system is a key function demonstrated by the metastatic cancer cell, xenograft models, by necessity, subvert this step.
  • With these limitations, studies of metastasis may require development of models of autochthonous tumors, that is, tumors originating in the study animals.
  • A number of cell lines of autochthonous murine tumors have been established that generate metastatic disease after implantation into mice.
  • Moreover, some transgenic animals spontaneously develop metastatic tumors that, although occurring in genetically engineered animals, may represent the most complete model from early development to late effects.
  • Finally, a very promising field of autochthonous tumor studies lies in work with companion animals (pets).
  • Some dogs will have cancer, often with striking similarities to those of their human counterparts.
  • In all of these cases, the tumor, new vasculature, and the immune system are syngeneic with the host.
  • In addition to the advances in model systems, advances in technology will further our understanding and ability to combat metastatic disease.
  • As demonstrated, genomics is proving to be a powerful tool in identifying those at risk for metastasis.
  • Clearly, therefore, a synthesis of different technologies and complimentary information will be required to target metastases and improve the outcome for patients affected by them.
  • [MeSH-major] Lung / immunology. Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Neoplasm Metastasis / genetics. Neoplasm Metastasis / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805200.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


86. Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, He QJ, Yang B: Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther; 2010 Aug;334(2):489-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors remain a significant health threat, with death often occurring as a result of metastasis.
  • Cell adhesion is a crucial step in the metastatic cascade of tumor cells, and interruption of this step is considered to be a logical strategy for prevention and treatment of tumor metastasis.
  • Here, we found that celastrol inhibited cell-extracellular matrix (ECM) adhesion of human lung cancer 95-D and mouse melanoma B16F10 cells.
  • Finally, the antimetastatic activity of celastrol was examined in vivo using the B16F10-green fluorescent protein-injected C57BL/6 mouse model, as indicated by decreased pulmonary metastases in celastrol-administrated mice.
  • [MeSH-major] Antigens, CD29 / physiology. Antineoplastic Agents, Phytogenic / pharmacology. Extracellular Matrix / physiology. Neoplasm Metastasis / drug therapy. p38 Mitogen-Activated Protein Kinases / physiology
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Enzyme Activation. Fibronectins / physiology. Humans. Mice. Mice, Inbred C57BL. Neoplasm Invasiveness. Proto-Oncogene Proteins c-akt / physiology. Signal Transduction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20472666.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Antineoplastic Agents, Phytogenic; 0 / Fibronectins; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


87. Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Bottos A, Gammaitoni L, Migliardi G, Camussi G, Alberghini M, Torchio B, Ferrari S, Bussolino F, Fagioli F, Picci P, Aglietta M: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer; 2009;8:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
  • BACKGROUND: Osteosarcoma (OS) is the most common primary bone tumour in children and young adults.
  • Despite improved prognosis, metastatic or relapsed OS remains largely incurable and no significant improvement has been observed in the last 20 years.
  • Sorafenib inhibited OS cell line proliferation, induced apoptosis and downregulated P-ERK1/2, MCL-1, and P-ERM in a dose-dependent manner.
  • In addition, sorafenib treatment dramatically reduced tumour volume of OS xenografts and lung metastasis in SCID mice.
  • Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs.
  • These data support the testing of sorafenib as a potential therapeutic option in metastatic or relapsed OS patients unresponsive to standard treatments.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Division / drug effects. Cell Line, Tumor. Down-Regulation / drug effects. Female. Humans. Male. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase Inhibitors. Mice. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Metastasis / prevention & control. Neovascularization, Pathologic / prevention & control. Niacinamide / analogs & derivatives. Phenylurea Compounds. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / biosynthesis


88. Venugopal B, Evans TR: Coexistent malignant melanoma and renal cell carcinoma. Tumori; 2009 Jul-Aug;95(4):518-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent malignant melanoma and renal cell carcinoma.
  • Patients with malignant melanoma are at an increased risk of developing subsequent primary melanomas and also nonmelanoma cutaneous cancers.
  • Several studies have reported an association between malignant melanoma and breast cancer, bladder cancer, colorectal cancer, neuroectodermal tumours, non-Hodgkin's lymphoma, leukaemia and renal cell carcinoma.
  • We report a case series of patients with a diagnosis of malignant melanoma who also developed a renal mass.
  • In two of these cases, the renal mass became apparent on diagnostic imaging as part of the staging investigations at the time of initial diagnosis of the malignant melanoma.
  • In both of these cases, biopsy of the renal mass confirmed the presence of a separate primary renal cell carcinoma which had presented concurrently with the malignant melanoma.
  • A third case presented with bone metastases ten years after excision of a thin melanoma.
  • Further imaging revealed pulmonary metastases and a renal mass, biopsy of which confirmed renal cell carcinoma.
  • The histology of this lesion was in keeping with metastatic melanoma, and the patient's past history included a diagnosis of ocular melanoma eight years prior to the development of metastatic disease in the right kidney.
  • Survival rates for patients with many types of malignant disease are improving, and there have been significant advances in clinical imaging techniques.
  • Consequently the development and detection of a second primary cancer, either presenting concurrently or on subsequent follow-up, is likely to be increasingly observed.
  • The series of patients reported here highlights the importance of a diagnostic biopsy in patients with malignant melanoma who develop a renal mass in order to establish a diagnosis and to plan optimal treatment.


89. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V: Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast; 2006 Apr;15(2):219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
  • The intention of this retrospective analysis was to describe the characteristics of patients with brain metastasis (BM) receiving trastuzumab for HER2 overexpressing metastatic breast cancer (MBC).
  • There was no correlation of the development of BM with regard to tumor grading and patient age.
  • In patients who developed BM, the median interval between visceral and brain metastasis was 14 months (range 0-69 months).
  • Median survival from diagnosis of BM was 13 months (range 0-60 months).
  • The median overall survival calculated from first diagnosis of metastasis was not significantly shorter in patients with BM than in patients without BM (37 vs. 47 months; P=0.07 log rank).
  • Trastuzumab is highly effective for the treatment of liver and lung metastasis in HER2 overexpressing patients, while it is apparently ineffective for treating or preventing BM.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Drug Administration Schedule. Female. Germany / epidemiology. Humans. Immunohistochemistry. Medical Records. Middle Aged. Neoplasm Metastasis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Analysis. Trastuzumab


90. Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, Plaschkes J, Perilongo G, Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL): Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer; 2005 May;41(7):1031-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL).
  • Our main aim in this paper is to present the surgical recommendations of the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL), as well as to stimulate international debate on this issue.
  • We discuss biopsy, verification of resectability, resection principles, indications and potential contraindications for orthotopic liver transplant, as well as thoracic surgery for pulmonary metastases.
  • We suggest that heroic liver resections with a high probability of leaving residual tumour should be avoided whenever possible.
  • We recommend early referral to a transplant surgeon in cases of: (i) multifocal or large solitary PRETEXT IV (PRE Treatment EXTent of disease scoring system) hepatoblastoma involving all four sectors of the liver and (ii) unifocal, centrally located tumours involving main hilar structures or main hepatic veins.
  • Because complete tumour resection is a prerequisite for cure, any strategy leading to an increased resection rate will result in improved survival.
  • These guidelines should not be seen as final, but rather as a starting point for further discussion between the various national and international liver tumour study groups.

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862752.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


91. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, Moehler M, Gockel I: High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol; 2009 May 7;15(17):2089-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells.
  • METHODS: The impact of miR-196a on the restriction targets HoxA7, HoxB8, HoxC8 and HoxD8 was analyzed by reverse transcription polymerase chain reaction (RT-PCR) after transient transfection of SW480 cancer cells.
  • The miR-196a transcription profile in colorectal cancer samples, mucosa samples and diverse cancer cell lines was quantified by RT-PCR.
  • Transiently miR-196a-transfected colorectal cancer cells were used for diverse functional assays in vitro and for a xenograft lung metastasis model in vivo.
  • RESULTS: HoxA7, HoxB8, HoxC8 and HoxD8 were restricted by miR-196a in a dose-dependent and gene-specific manner.
  • In addition, high levels of miR-196a promoted cancer cell detachment, migration, invasion and chemosensitivity towards platin derivatives but did not impact on proliferation or apoptosis.
  • Furthermore, miR-196a increased the development of lung metastases in mice after tail vein injection.
  • CONCLUSION: miR-196a exerts a pro-oncogenic influence in colorectal cancer.
  • [MeSH-minor] Animals. Cell Adhesion / physiology. Cell Line, Tumor. Cell Proliferation. Colon / anatomy & histology. Colon / physiology. Humans. Mice. Neoplasm Transplantation. Signal Transduction / physiology. Transcription, Genetic. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] Oncogene. 2001 Sep 6;20(39):5440-8 [11571641.001]
  • [Cites] Cell. 2001 Dec 28;107(7):823-6 [11779458.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):162-9 [11813208.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):363-4 [11896390.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Science. 2003 Jul 18;301(5631):336-8 [12869753.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5879-88 [14522913.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(4):303-24 [6394125.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1727-31 [1516027.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] EMBO J. 1993 Oct;12(10):3835-46 [8104786.001]
  • [Cites] Tumour Biol. 1996;17(1):34-47 [7501971.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51581-9 [15358764.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):49-58 [15659339.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):671-4 [16319892.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1133-46 [16337999.001]
  • [Cites] Med Hypotheses. 2006;66(3):612-35 [16359827.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] DNA Cell Biol. 2007 May;26(5):293-300 [17504025.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 7;272(2):513-8 [10833444.001]
  • (PMID = 19418581.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MIRN196 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2678579
  •  go-up   go-down


92. Il'nitskaia SI, Nikolin VP, Popova NA, Avgustinovich DF, Kaledin VI, Kudriavtseva NN: [Effects of ethanol on metastasis of Lewis lung carcinoma in male mice with different social states]. Ross Fiziol Zh Im I M Sechenova; 2009 Jan;95(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of ethanol on metastasis of Lewis lung carcinoma in male mice with different social states].
  • The aim of this work was to study the effect of ethanol on experimental metastasis of Lewis lung carcinoma in male mice in positive or negative emotional states.
  • Tumor cells were injected into the tail vein after 20 days of agonistic interactions, and the number of metastases in the lung was calculated 16 days later.
  • Mice of all experimental groups were chronically treated with ethanol (20%, 2 ml/kg of weight, i.p.) and saline during 7 days starting with the day of tumor cells injections.
  • The experimental metastasis was shown to develop differently in mice with opposing social experience: saline-treated winners had significantly less metastases in the lung than the saline-treated losers.
  • Chronic ethanol injections decreased the number of metastases in the losers, increased it in the winners and did not affect the controls.
  • The results obtained indicate that effects if ethanol on Lewis lung carcinoma metastasis depend on psychoemotional status in male mice.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323446.001).
  • [ISSN] 0869-8139
  • [Journal-full-title] Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova
  • [ISO-abbreviation] Ross Fiziol Zh Im I M Sechenova
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 3K9958V90M / Ethanol
  •  go-up   go-down


93. Sawabata N: Detecting metastasis of lung cancer in mediastinal lymph nodes: the discrepancy between cytology and histology. Ann Thorac Surg; 2006 Apr;81(4):1547; author reply 1547
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting metastasis of lung cancer in mediastinal lymph nodes: the discrepancy between cytology and histology.
  • [MeSH-major] Lung Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Mediastinum. Pathology / standards

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Thorac Surg. 2004 Oct;78(4):1190-3 [15464468.001]
  • (PMID = 16564322.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Zhang Q, Niu XH, Cai YB, Hao L, Ding Y, Yu F: [Total femoral prosthesis replacement in management of femoral malignant bone tumor]. Zhonghua Wai Ke Za Zhi; 2007 May 15;45(10):661-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total femoral prosthesis replacement in management of femoral malignant bone tumor].
  • OBJECTIVE: To discuss the indications of reconstruction with total femoral prosthesis for the patients with a majority of femur infiltrated by malignant bone tumor, and to evaluate the functional outcome and complication.
  • METHODS: Between October 1996 and October 2002, 17 patients with malignant bone tumor were treated with total femoral prosthesis replacement.
  • The extent of lesions was 23-28 cm (a majority of femur infiltrated by malignant bone tumor).
  • Preoperative pathologic diagnosis were established by open biopsy (2 cases) or needle biopsy (15 cases).
  • RESULTS: Seventeen cases were followed up with a mean time of 45 months (range 9-120 months).
  • In 12 IIB cases, 4 cases (33%) developed pulmonary metastasis and died.
  • In 5 IIIB cases, all with a mean survived term of 13 months (range 9-20 months) died.
  • CONCLUSIONS: Total femoral prosthesis replacement could be used in the treatment of the patients with a majority of femur infiltrated by malignant bone tumor and could effectively recover their limb function to a great extent.
  • The procedure can effectively improve the quality of life for the patients with malignant bone tumor staging IIIB.

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688815.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Krieger-Hinck N, Schumacher U, Müller A, Valentiner U: The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model. Oncol Res; 2010;18(8):387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model.
  • In the present study, SK-N-SH neuroblastoma cells were subcutaneously injected into SCID mice and their growth and metastatic behavior under the treatment with rosiglitazone was analyzed.
  • Therapeutic effects were evaluated comparing primary tumor weight, cell proliferation, apoptosis, and number of pulmonary metastasis.
  • However, primary tumor weight, apoptosis, and metastasis were not considerably influenced.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Male. Mice. Mice, Inbred BALB C. Mice, SCID. Neoplasm Metastasis. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441053.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PPAR gamma; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone
  •  go-up   go-down


96. Ting PT, Burrowes PW, Gray RR: Intravascular pulmonary metastases from sarcoma: appearance on computed tomography in 3 cases. Can Assoc Radiol J; 2005 Oct;56(4):214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular pulmonary metastases from sarcoma: appearance on computed tomography in 3 cases.
  • INTRODUCTION: Various common malignant neoplasms (ie, liver, kidney, stomach, and breast) have been reported to embolize to the pulmonary arterial system.
  • This uncommon occurrence can also result from metastatic sarcoma.
  • We report 3 cases--2 chondrosarcomas and 1 osteosarcoma-associated with intravascular metastases to the pulmonary vasculature and discuss the clinical presentation and differentiating radiologic features on computed tomography (CT).
  • DISCUSSION: Intravascular pulmonary tumour emboli may present with nonspecific respiratory symptoms or remain completely asymptomatic, and therefore, many patients are often misdiagnosed with thromboembolic disease or undiagnosed until autopsy.
  • Chest CTs in all our patients demonstrated a striking pattern of multifocal tubular branching beaded opacities along the pulmonary vasculature in a multilobular distribution.
  • CONCLUSION: Our observations and a review of the literature indicate that chest CT is the most useful diagnostic tool for detecting intravascular pulmonary tumour emboli.
  • The tubular nature of these metastases distinguishes them from the more common parenchymal metastases.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma / radiography. Chondrosarcoma / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Osteosarcoma / radiography. Osteosarcoma / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Male


97. Yoshioka I, Tsuchiya Y, Aozuka Y, Onishi Y, Sakurai H, Koizumi K, Tsukada K, Saiki I: Urinary trypsin inhibitor suppresses surgical stress-facilitated lung metastasis of murine colon 26-L5 carcinoma cells. Anticancer Res; 2005 Mar-Apr;25(2A):815-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary trypsin inhibitor suppresses surgical stress-facilitated lung metastasis of murine colon 26-L5 carcinoma cells.
  • Recently, we have reported that surgical stress promoted the metastasis of murine colon carcinoma cells to the lung by inducing the expression of proteases such as matrix metalloprotease-9 (MMP-9) in lung tissue.
  • The purpose of this study was to investigate the anti-metastatic properties of UTI in an animal model of surgical stress-induced cancer metastasis.
  • The intraperitoneal administration of UTI after the intravenous injection of colon 26-L5 carcinoma (colon 26-L5) cells into mice subjected to surgical stress suppressed the enhancement of lung metastasis (p<0.05).
  • Furthermore, we investigated the effect of UTI on tumor growth, adhesion to fibronectin, migration, invasion and enzymatic degradation in colon 26-L5.
  • UTI may improve therapeutic efficacy in cancer patients after major surgery.
  • [MeSH-major] Colonic Neoplasms / pathology. Glycoproteins / pharmacology. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Stress, Physiological / pathology
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Growth Processes / drug effects. Cell Movement / drug effects. Female. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase Inhibitors. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Trypsin Inhibitors / pharmacology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868913.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / Trypsin Inhibitors; 80449-32-7 / urinastatin; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


98. Granić M, Oprić D, Pupić G, Babić D, Ivanović N, Nikolić D, Dikić S, Oprić S: [Surgical methods for the treatment of breast phyllodes tumors--a report of 319 cases]. Acta Chir Iugosl; 2006;53(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biologicaly they can be divided into benign, borderline and malignant group.
  • Incomplete tumor excision can be the reason for local reccurence.
  • Malignant form of FT metastazise hematogenous most often in the lung.
  • -31.12.1994. Retrospective study of surgical treatment 84 patients with FT of the breast (69 benign, 4 borderline and 11 malignant) and 5 year follow up after surgery we analysed.
  • RESULTS: local reccurence after surgery was found in 17 (20,2 %) patients(14 benign , 2 borderline and 1 malignant FT), pulmonary metastases in 6 (7,1%) patients with malignant FT.
  • DFI was 21,3 months for local reccurences and 25,1 months for pulmonary metastases.
  • CONCLUSION: According to biological behavior we propose wide excision for benign and borderline forms and simple mastectomy for malignant FT, and voluminous benign and borderline forms.
  • Axillary disection is not necessary because lymphatic spread of malignant FT is unfrequent.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989148.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


99. Sakurai J, Hiraki T, Mimura H, Gobara H, Fujiwara H, Tajiri N, Sano Y, Kanazawa S: Radiofrequency ablation of small lung metastases by a single application of a 2-cm expandable electrode: determination of favorable responders. J Vasc Interv Radiol; 2010 Feb;21(2):231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of small lung metastases by a single application of a 2-cm expandable electrode: determination of favorable responders.
  • PURPOSE: To determine which lung metastases are most likely to be treated effectively with a single radiofrequency (RF) application (defined as two separate applications of RF energy at a single electrode position) with a multitined expandable electrode with arrays 2 cm in diameter.
  • MATERIALS AND METHODS: The authors retrospectively evaluated 88 lung metastases (mean long-axis diameter, 0.9 cm) in 36 patients (20 men and 16 women; mean age, 57 years) treated with a single RF application with a multitined expandable electrode with arrays 2 cm in diameter.
  • Then, the technique effectiveness rates were again estimated when considering only metastases without risk factors and compared with those of other tumors.
  • Tumor size greater than 1.0 cm (P = .033) and contact with the bronchus with an inner diameter of at least 2 mm (P = .047) were the significant risk factors for local progression.
  • The technique effectiveness rates for metastases 1.0 cm or smaller that were not in contact with the bronchus (n = 59) were 96% at 1 year and at 2 years; those rates were significantly (P = .010) higher than those in other tumors (n = 29).
  • CONCLUSIONS: A single RF application with a multitined expandable electrode with arrays 2 cm in diameter is most likely to suffice in small (<or=1 cm) lung metastases not in contact with a bronchus.
  • [MeSH-major] Catheter Ablation / instrumentation. Lung Neoplasms / surgery. Patient Selection

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20022763.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. El Fekih L, Hassene H, Fenniche S, Ben Abdelghaffar H, Belhabib D, Megdiche ML: Pulmonary metastases revealing choriocarcinoma. Tunis Med; 2010 Jan;88(1):49-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastases revealing choriocarcinoma.
  • BACKGROUND: Uterin choriocarcinoma is a trophoblastic tumour characterised by high metastasis potential.
  • Pleuropulmonary metastasis can reveal rarely the neoplasm.
  • CASE REPORT: We report the case of a 31-years-old woman, with no pathological antecedent, admitted in our department for thoracic pain and haemoptysis occurring two months after delivery of a did in child-birth.
  • A diagnosis of metastatic choriocarcinoma was confirmed by plasmatic level of beta human chorionic gonadotrophin (beta HCG) superior to 4000 UI/ml.
  • Patient died after 3 cures of chemotherapy because of acute respiratory failure caused by massive pulmonary embolism.
  • CONCLUSION: Diagnosis of choriocarcinoma must be evocated in front of several pulmonary opacities occurring in genital activity women and necessities the dosage of level of BHCG.
  • [MeSH-major] Biomarkers, Tumor / blood. Choriocarcinoma / secondary. Chorionic Gonadotropin, beta Subunit, Human / blood. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Hemoptysis / etiology. Humans. Postpartum Period. Pregnancy. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415215.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down






Advertisement